Peter Greenberg

5.0/5

Biography

As Director of the Stanford MDS Center, Dr Greenberg has an active clinical practice focusing on myelodysplastic syndromes (MDS) and clonal myeloid disorders. His clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the impact of molecular mutations for a risk-based prognostic system, the IPSS-Molecular (IPSS-M). He is Chair of the NCCN Practice Guidelines Panel for MDS. His prior laboratory investigations included biologic studies of MDS-related myeloid progenitor cell proliferation as well as mutational and transcriptomic evaluation of gene expression profiles contributing to prognosis in MDS. His current investigations include evaluation of ex vivo drug sensitivity methods for identifying potentially useful and often novel therapeutic drugs for patients with myeloid neoplasms refractory to standard therapies.

View Full Biography

Professional Summary

Education & Certifications

Fellowship: Stanford University Hematology and Oncology Fellowship (1971) CA
Residency: Stanford University Internal Medicine Residency (1968) CA
Residency: Barnes and Allied Hospitals/Washington University School of Med (1965) MO
- Internship: Barnes and Allied Hospitals/Washington University School of Med (1964) MO
- Medical Education: George Washington University School of Medicine and Health Sciences (1963) DC
- Board Certification: American Board of Internal Medicine, Hematology (1976)
- Board Certification: American Board of Internal Medicine, Internal Medicine (1970)
- B.A., Johns Hopkins University, Biological Sciences (1959)
- M.D., George Washington U Med School, Medicine (1963)

View More Education & Certifications

Honors & Awards

International Prize for outstanding research in myelodysplastic syndromes (MDS), J.P. McCarthy Foundation (1997)
Lifetime Achievement Award for MDS, International Workshop for MDS (2022)

Memberships

Member, American Society of Hematology (1972 - Present)
Member, Eastern Cooperative Oncology Group, Leukemia Committee (1993 - 2018)
Chairman, NCCN Myelodysplastic Syndrome Guidelines Panel (1997 - Present)
- Coordinator, International Working Group for Prognosis in MDS (IWG-PM) (2009 - Present)
- Executive Committee, MDS Foundation, Inc (2009 - Present)
- Member, World Health Organization Clinical Advisory Committee for Myeloid Malignancies (2014 - Present)

View More Memberships

Administrative Appointments

Acting Chief, Medical Service, VA Palo Alto Health Care System (1978 - 1979)
Chair, National Comprehensive Cancer Network Myelodysplastic Syndromes Practice Guidelines Panel (1997 - 2023)
Coordinator, International Working Group for Prognosis in MDS (2009 - 2023)
- Director, Stanford MDS Center (1998 - 2023)
- Head, Hematology Section, VA Palo Alto Health Care System (1979 - 2005)
- Member, Stanford Scientific Review Committee (2009 - 2023)

View More Administrative Appointments

Publications

Prognostic scoring systems for risk assessment in myelodysplastic syndromes.
Greenberg, P. L., Sanz, G. F., & Sanz, M. A. (1999). Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Forum (Genoa, Italy), 9(1), 17–31.
Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes
Greenberg, P. (2001). Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes. LANCET, 357(9262), 1059–60.
Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines
Greenberg, P. (2001). Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines. ANNALS OF THE RHEUMATIC DISEASES, 60, III41–III42.
- Myelodysplastic syndromes.
  Greenberg, P. L., Young, N. S., & Gattermann, N. (2002). Myelodysplastic syndromes. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 136–61.
- Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study
  Cherry, A. M., Brockman, S. R., Paternoster, S. F., Hicks, G. A., Neuberg, D., Higgins, R. R., … DeWald, G. W. (2003). Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. LEUKEMIA RESEARCH, 27(12), 1085–90.
- TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS
  Greenberg, P. L. (1992). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS. SEMINARS IN ONCOLOGY, 19(1), 106–14.
- T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW
  SCHMIDTWOLF, I. G. H., DEJBAKHSHJONES, S., Ginzton, N., Greenberg, P., & Strober, S. (1992). T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW. BLOOD, 80(12), 3242–50.
- Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
  Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., … Rowe, J. M. (2004). Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). JOURNAL OF CLINICAL ONCOLOGY, 22(6), 1078–86.
- Management of patients with higher risk myelodysplastic syndromes
  Fukumoto, J. S., & Greenberg, P. L. (2005). Management of patients with higher risk myelodysplastic syndromes. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 56(2), 179–92.
- Myelodysplastic syndromes clinical practice guidelines in oncology.
  Greenberg, P. L., Baer, M. R., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., … Tallman, M. S. (2006). Myelodysplastic syndromes clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(1), 58–77.
- Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
  Greenberg, P. L. (2006). Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Journal of the National Comprehensive Cancer Network , 4(1), 91–96.
- HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE
  LEWINSOHN, D. M., Nagler, A., Ginzton, N., Greenberg, P., & BUTCHER, E. C. (1990). HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE. BLOOD, 75(3), 589–95.
- EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES
  Nagler, A., Ginzton, N., Negrin, R., Bang, D., Donlon, T., & Greenberg, P. (1990). EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 4(3), 193–202.
- EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
  Greenberg, P., Negrin, R., Nagler, A., Vincent, M., & Donlon, T. (1990). EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR. Presented at the 2ND INTERNATIONAL CONF ON BLOOD CELL GROWTH FACTORS : THEIR BIOLOGY AND CLINICAL APPLICATIONS, CAPRI,ITALY,ITALY,ITALY: ALPHAMED PRESS.
- MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
  Negrin, R. S., HAEUBER, D. H., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., … Greenberg, P. L. (1990). MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR. BLOOD, 76(1), 36–43.
- EFFECTS OF CSFS IN PRELEUKEMIA
  Greenberg, P. L., Negrin, R., & Nagler, A. (1990). EFFECTS OF CSFS IN PRELEUKEMIA. Presented at the 3RD INTERNATIONAL SYMP ON MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA, ROTTERDAM,NETHERLANDS,NETHERLANDS,NETHERLANDS,NETHERLANDS,NETHERLANDS,NETHERLANDS,NETHERLANDS,NETHERLANDS,NETHERLANDS,NETHERLANDS: STOCKTON PRESS.
- IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF
  Nagler, A., Binet, C., MacKichan, M. L., Negrin, R., Bangs, C., Donlon, T., & Greenberg, P. (1990). IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF. BLOOD, 76(7), 1299–1307.
- FUNCTIONAL INTERACTIONS BETWEEN COLONY-STIMULATING FACTORS AND THE INSULIN FAMILY HORMONES FOR HUMAN MYELOID LEUKEMIC-CELLS
  Oksenberg, D., DIECKMANN, B. S., & Greenberg, P. L. (1990). FUNCTIONAL INTERACTIONS BETWEEN COLONY-STIMULATING FACTORS AND THE INSULIN FAMILY HORMONES FOR HUMAN MYELOID LEUKEMIC-CELLS. CANCER RESEARCH, 50(20), 6471–77.
- TREATMENT OF MYELODYSPLASTIC SYNDROMES
  Greenberg, P. L. (1991). TREATMENT OF MYELODYSPLASTIC SYNDROMES. BLOOD REVIEWS, 5(1), 42–50.
- INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES
  Greenberg, P. L. (1992). INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES. SEMINARS IN ONCOLOGY, 19(1), 34–46.
- Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
  Porter, J., Galanello, R., Saglio, G., Neufeld, E. J., Vichinsky, E., Cappellini, M. D., … Rose, C. (2008). Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. EUROPEAN JOURNAL OF HAEMATOLOGY, 80(2), 168–76.
- Myelodysplastic syndromes.
  Greenberg, P. L., Attar, E., Battiwalla, M., Bennett, J. M., Bloomfield, C. D., DeCastro, C. M., … Westervelt, P. (2008). Myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network , 6(9), 902–26.
- The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
  Greenberg, P. L., Cosler, L. E., Ferro, S. A., & Lyman, G. H. (2008). The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. Journal of the National Comprehensive Cancer Network , 6(9), 942–53.
- A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
  Gotlib, J., Lavori, P., Quesada, S., Stein, R. S., Shahnia, S., & Greenberg, P. L. (2009). A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY, 84(1), 15–20.
- EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS
  Greenberg, P. L. (1991). EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS. BLOOD CELLS, 17(2), 344–46.
- Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
  Greenberg, P. L., Sun, Z., Miller, K. B., Bennett, J. M., Tallman, M. S., Dewald, G., … Rowe, J. M. (2009). Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). BLOOD, 114(12), 2393–2400.
- Relationship of differential gene expression profiles in CD34(+) myelodysplastic syndrome marrow cells to disease subtype and progression
  Sridhar, K., Ross, D. T., Tibshirani, R., Butte, A. J., & Greenberg, P. L. (2009). Relationship of differential gene expression profiles in CD34(+) myelodysplastic syndrome marrow cells to disease subtype and progression. BLOOD, 114(23), 4847–58.
- Current therapeutic approaches for patients with myelodysplastic syndromes
  Greenberg, P. L. (2010). Current therapeutic approaches for patients with myelodysplastic syndromes. BRITISH JOURNAL OF HAEMATOLOGY, 150(2), 131–43.
- Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes
  Greenberg, P. L., Koller, C. A., Cabantchik, Z. I., Warsi, G., Glynos, T., Paley, C., & Schiffer, C. (2010). Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. LEUKEMIA RESEARCH, 34(12), 1560–65.
- NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.
  Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., … Westervelt, P. (2011). NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network , 9(1), 30–56.
- BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND NATURAL-KILLER-CELLS
  Nagler, A., & Greenberg, P. L. (1990). BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND NATURAL-KILLER-CELLS. INTERNATIONAL JOURNAL OF CELL CLONING, 8(3), 171–83.
- Myelodysplastic Syndromes: Dissecting the Heterogeneity
  Greenberg, P. L. (2011). Myelodysplastic Syndromes: Dissecting the Heterogeneity. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1937–38.
- Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na
  Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., Felsher, D. W., … Greenberg, P. L. (2012). Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. LEUKEMIA RESEARCH, 36(1), 98–103.
- Molecular and genetic features of myelodysplastic syndromes
  Greenberg, P. L. (2012). Molecular and genetic features of myelodysplastic syndromes. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 34(3), 215–22.
- Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes
  Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y. K., Chen, R., … Snyder, M. (2012). Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes. CELL, 148(6), 1293–1307.
- Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow
  Flores-Figueroa, E., Varma, S., Montgomery, K., Greenberg, P. L., & Gratzinger, D. (2012). Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow. LABORATORY INVESTIGATION, 92(9), 1330–41.
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
  Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., … Haase, D. (2012). Revised International Prognostic Scoring System for Myelodysplastic Syndromes. BLOOD, 120(12), 2454–65.
- Reduced rRNA expression and increased rDNA promoter methylation in CD34(+) cells of patients with myelodysplastic syndromes
  Raval, A., Sridhar, K. J., Patel, S., Turnbull, B. B., Greenberg, P. L., & Mitchell, B. S. (2012). Reduced rRNA expression and increased rDNA promoter methylation in CD34(+) cells of patients with myelodysplastic syndromes. BLOOD, 120(24), 4812–18.
- Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
  Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96.
- Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials
  Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., Hoppe, R. T., & Advani, R. H. (2013). Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials. JOURNAL OF CLINICAL ONCOLOGY, 31(5), 592–98.
- Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
  Pang, W. W., Pluvinage, J. V., Price, E. A., Sridhar, K., Arber, D. A., Greenberg, P. L., … Weissman, I. L. (2013). Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(8), 3011–16.
- TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL
  Negrin, R. S., HAEUBER, D. H., Nagler, A., Olds, L. C., Donlon, T., SOUZA, L. M., & Greenberg, P. L. (1989). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL. ANNALS OF INTERNAL MEDICINE, 110(12), 976–84.
- BIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES
  Greenberg, P. L. (1987). BIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES. ACTA HAEMATOLOGICA, 78, 94–99.
- SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN-2 STIMULATED HUMAN LYMPHOCYTES-T AND NATURAL-KILLER CELLS
  Skettino, S., Phillips, J., Lanier, L., Nagler, A., & Greenberg, P. (1988). SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN-2 STIMULATED HUMAN LYMPHOCYTES-T AND NATURAL-KILLER CELLS. BLOOD, 71(4), 907–14.
- RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II FOR HUMAN MYELOID LEUKEMIC-CELLS
  PEPE, M. G., Ginzton, N. H., Lee, P. D. K., Hintz, R. L., & Greenberg, P. L. (1987). RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II FOR HUMAN MYELOID LEUKEMIC-CELLS. JOURNAL OF CELLULAR PHYSIOLOGY, 133(2), 219–27.
- IMMUNOLOGICAL SELECTION OF HEMATOPOIETIC PRECURSOR CELLS UTILIZING ANTIBODY-MEDIATED PLATE BINDING (PANNING)
  Greenberg, P. L., Baker, S., Link, M., & Minowada, J. (1985). IMMUNOLOGICAL SELECTION OF HEMATOPOIETIC PRECURSOR CELLS UTILIZING ANTIBODY-MEDIATED PLATE BINDING (PANNING). BLOOD, 65(1), 190–97.
- EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES
  Nagler, A., MacKichan, M. L., Negrin, R. S., Donlon, T., & Greenberg, P. L. (1995). EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 9(1), 30–39.
- ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION
  Schriber, J. R., DEJBAKHSHJONES, S., KUSNIERZGLAZ, C. R., Ginzton, N., Still, B., Negrin, R. S., … Strober, S. (1995). ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION. EXPERIMENTAL HEMATOLOGY, 23(9), 1024–29.
- TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN
  Negrin, R. S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S., & Greenberg, P. L. (1993). TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN. BLOOD, 82(3), 737–43.
- MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF
  Han, J. H., Gileadi, C., Rajapaksa, R., Kosek, J., & Greenberg, P. L. (1995). MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF. EXPERIMENTAL HEMATOLOGY, 23(3), 265–72.
- Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
  Negrin, R. S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S., & Greenberg, P. L. (1996). Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. BLOOD, 87(10), 4076–81.
- Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes
  Greenberg, P. L. (1996). Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. SEMINARS IN HEMATOLOGY, 33(2), 163–75.
- Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
  Rajapaksa, R., Ginzton, N., Rott, L. S., & Greenberg, P. L. (1996). Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. BLOOD, 88(11), 4275–87.
- GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation
  Greenberg, P., Advani, R., Keating, A., Gulati, S. C., Nimer, S., Champlin, R., … Cuffie, C. (1996). GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. BONE MARROW TRANSPLANTATION, 18(6), 1057–64.
- International scoring system for evaluating prognosis in myelodysplastic syndromes
  Greenberg, P., Cox, C., LEBEAU, M. M., Fenaux, P., Morel, P., Sanz, G., … Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. BLOOD, 89(6), 2079–88.
- Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression
  Davis, R. E., & Greenberg, P. L. (1998). Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. LEUKEMIA RESEARCH. NASHVILLE,TN,TN,TN,TN,TN,TN,TN,TN,TN,TN,TN: PERGAMON-ELSEVIER SCIENCE LTD.
- Risk factors and their relationship to prognosis in myelodysplastic syndromes
  Greenberg, P. L. (1998). Risk factors and their relationship to prognosis in myelodysplastic syndromes. LEUKEMIA RESEARCH, 22, S3–S6.
- Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment
  Greenberg, P. L. (1998). Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. LEUKEMIA RESEARCH, 22(12), 1123–36.
- Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size
  Greenberg, P. L. (1992). Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size. Focus on Growth Factors, 3(2).
- NCCN Practice Guidelines for Myelodysplastic Syndromes
  NCCN Practice Guidelines for Myelodysplastic Syndromes. (1998). Oncology, 12(11A).
- The Myelodysplastic Syndromes .
  Greenberg, P. (2000). The Myelodysplastic Syndromes . HEMATOLOGY:BASIC PRINCIPLES AND PRACTICE 3rd Ed., Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, Eds. Churchill Livingstone, NY,
- A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes: Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome
  A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes: Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome. (2004). Blood, 104.
- Novel biospecific agents for the treatment of myelodysplastic syndromes.
  Novel biospecific agents for the treatment of myelodysplastic syndromes. (2003). J Nat Comprehensive Cancer Network, 1.
- Myelodysplastic Syndromes: Clinical and Biological Advances
  Greenberg, P. L. L. (2006). Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge University Press, Cambridge, England.
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. (2006). Blood, 108.
- Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q.
  Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q. (2008). Blood, 111.
- Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study.
  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study. (2008). Eur J Haematol, 80.
- Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF
  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF. (2008). Blood, 111.
- International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed: Impact of cytopenias on clinical outcomes in Myelodysplastic Syndrome
  Kao, J. M., McMillan, A., & Greenberg, P. L. (2008). International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed: Impact of cytopenias on clinical outcomes in Myelodysplastic Syndrome. Am J Hematology, 83.
- A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia
  A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia. (2006). Blood, 108.
- Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion.
  Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. (2006). New Eng J Med, 355.
- Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference
  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference. (2007). Leukemia Research, 31.
- Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods
  Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods. (2007). Clinical Leukemia, 1.
- NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes
  NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes. (2009). J Nat Comp Cancer Network, 7(Suppl 9).
- Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow
  Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow. (2012). Lab Investigation, 92.
- A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
  Cutler, C. S., Lee, S. J., Greenberg, P., Deeg, H. J., Perez, W. S., Anasetti, C., … Horowitz, M. M. (2004). A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. BLOOD, 104(2), 579–85.
- Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
  List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., … Knight, R. (2006). Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. NEW ENGLAND JOURNAL OF MEDICINE, 355(14), 1456–65.
- Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
  Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, J., … List, A. F. (2008). Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. BLOOD, 111(1), 86–93.
- PHASE-III RANDOMIZED MULTICENTER TRIAL OF G-CSF VS OBSERVATION FOR MYELODYSPLASTIC SYNDROMES (MDS)
  Greenberg, P., Taylor, K., Larson, R., Koeffler, P., Negrin, R., Saba, H., … Brown, S. (1993). PHASE-III RANDOMIZED MULTICENTER TRIAL OF G-CSF VS OBSERVATION FOR MYELODYSPLASTIC SYNDROMES (MDS). BLOOD, 82(10), A196–A196.
- INDUCTION OF HUMAN HEMATOPOIETIC STEM-CELL (CFU-GEMM) GROWTH BY FACTORS RELEASED FROM MITOGEN-STIMULATED SPLEEN-CELLS
  Fabian, I., Levitt, L., & Greenberg, P. (1982). INDUCTION OF HUMAN HEMATOPOIETIC STEM-CELL (CFU-GEMM) GROWTH BY FACTORS RELEASED FROM MITOGEN-STIMULATED SPLEEN-CELLS. ELSEVIER SCIENCE INC.
- PURE WHITE-CELL APLASIA - ANTIBODY-MEDIATED AUTOIMMUNE INHIBITION OF GRANULOPOIESIS
  Levitt, L. J., Ries, C. A., & Greenberg, P. L. (1983). PURE WHITE-CELL APLASIA - ANTIBODY-MEDIATED AUTOIMMUNE INHIBITION OF GRANULOPOIESIS. NEW ENGLAND JOURNAL OF MEDICINE, 308(19), 1141–46.
- THE CHRONIC IDIOPATHIC NEUTROPENIA SYNDROME - CORRELATION OF CLINICAL-FEATURES WITH INVITRO PARAMETERS OF GRANULOCYTOPOIESIS
  Greenberg, P. L., MARA, B., Steed, S., & Boxer, L. (1980). THE CHRONIC IDIOPATHIC NEUTROPENIA SYNDROME - CORRELATION OF CLINICAL-FEATURES WITH INVITRO PARAMETERS OF GRANULOCYTOPOIESIS. BLOOD, 55(6), 915–21.
- Phase it study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): Preliminary results
  Gotlib, J., Jamieson, C. H. M., List, A., Cortes, J., Albitar, M., Sridhar, K., … Greenberg, P. L. (2003). Phase it study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): Preliminary results. BLOOD, 102(11), 425A–425A.
- A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib)
  Fan, A. C., Xu, L., Sridhar, K. J., Tran, M., Banerjee, P., Renschler, J. P., … Felsher, D. W. (2011). A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib). BLOOD, 118(21), 1626–26.
- Phase I/II, randomized, MultiCenter, dose-ascension study of the p38MAPK inhibitor scio469 in patients with myelodysplastic syndrome (MDS).
  Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M. A., Parmar, S., Greenberg, P., … List, A. (2006). Phase I/II, randomized, MultiCenter, dose-ascension study of the p38MAPK inhibitor scio469 in patients with myelodysplastic syndrome (MDS). BLOOD, 108(11), 751A–751A.
- LITHIUM TREATMENT IN ADULTS WITH ACUTE MYELOID-LEUKEMIA RECEIVING CHEMOTHERAPY
  Horns, R. C., Schrier, S. L., & Greenberg, P. L. (1984). LITHIUM TREATMENT IN ADULTS WITH ACUTE MYELOID-LEUKEMIA RECEIVING CHEMOTHERAPY. MEDICAL AND PEDIATRIC ONCOLOGY, 12(3), 169–72.
- Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
  Koreth, J., Pidala, J., Perez, W. S., Deeg, H. J., Garcia-Manero, G., Malcovati, L., … Cutler, C. (2013). Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of Clinical Oncology , 31(21), 2662–2670.
- The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features
  Greenberg, P. L. (2013). The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(7), 877–85.
- Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: Evidence for in vivo synergy
  Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: Evidence for in vivo synergy. (1996). Blood, 87.
- Granulopoiesis in acute myeloid leukemia and preleukemia
  Granulopoiesis in acute myeloid leukemia and preleukemia. (1971). New Engl J Med, 284.
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
  Lancet, J. E., Gojo, I., Gotlib, J., Feldman, E. J., Greer, J., Liesveld, J. L., … Karp, J. E. (2007). A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. BLOOD, 109(4), 1387–94.
- Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
  Barreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., … Steidl, U. (2012). Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. BLOOD, 120(6), 1290–98.
- Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model
  HELLSTROMLINDBERG, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., … Greenberg, P. (1997). Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. BRITISH JOURNAL OF HAEMATOLOGY, 99(2), 344–51.
- MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
  Neubauer, A., Greenberg, P., Negrin, R., Ginzton, N., & Liu, E. (1994). MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 8(4), 638–41.
- NCCN Practice Guidelines for chronic myelogenous leukemia
  Talpaz, M., Berman, E., Clift, R. A., Copelan, E. A., Emanuel, P. D., Erba, H. P., … Talpaz, M. (2000). NCCN Practice Guidelines for chronic myelogenous leukemia. ONCOLOGY-NEW YORK, 14(11A), 229–40.
- Myelodysplastic Syndromes
  Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., … Naganuma, M. (2013). Myelodysplastic Syndromes. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(7), 838–74.
- MYELOPROLIFERATIVE DISORDERS - CORRELATION BETWEEN CLINICAL EVOLUTION AND ALTERATIONS OF GRANULOPOIESIS
  Greenberg, P., MARA, B., Bax, I., BROSSEL, R., & Schrier, S. (1976). MYELOPROLIFERATIVE DISORDERS - CORRELATION BETWEEN CLINICAL EVOLUTION AND ALTERATIONS OF GRANULOPOIESIS. AMERICAN JOURNAL OF MEDICINE, 61(6), 878–91.
- MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH INVASIVE FUNGAL DISEASE DURING REMISSION INDUCTION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA
  Schwartz, R. S., MacKintosh, F. R., Schrier, S. L., & Greenberg, P. L. (1984). MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH INVASIVE FUNGAL DISEASE DURING REMISSION INDUCTION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA. CANCER, 53(3), 411–19.
- GRANULOPOIESIS IN NEUTROPENIC DISORDERS
  GREENBER, P. L., & Schrier, S. L. (1973). GRANULOPOIESIS IN NEUTROPENIC DISORDERS. BLOOD, 41(6), 753–69.
- REMISSION MAINTENANCE THERAPY IN ACUTE MYELOGENOUS LEUKEMIA
  Embury, S. H., Elias, L., Heller, P. H., HOOD, C. E., Greenberg, P. L., & Schrier, S. L. (1977). REMISSION MAINTENANCE THERAPY IN ACUTE MYELOGENOUS LEUKEMIA. WESTERN JOURNAL OF MEDICINE, 126(4), 267–72.
- MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH OUTCOME OF TREATMENT FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA
  Schwartz, R. S., MacKintosh, F. R., Halpern, J., Schrier, S. L., & Greenberg, P. L. (1984). MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH OUTCOME OF TREATMENT FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA. CANCER, 54(8), 1672–81.
- CLINICAL UTILITY OF INVITRO EVALUATION OF GRANULOPOIESIS
  GREENBER, P. L., & Schrier, S. L. (1974). CLINICAL UTILITY OF INVITRO EVALUATION OF GRANULOPOIESIS. ANNUAL REVIEW OF MEDICINE, 25, 269–78.
- SUB-ACUTE MYELOID-LEUKEMIA - CLINICAL REVIEW
  Cohen, J. R., CREGER, W. P., Greenberg, P. L., & Schrier, S. L. (1979). SUB-ACUTE MYELOID-LEUKEMIA - CLINICAL REVIEW. AMERICAN JOURNAL OF MEDICINE, 66(6), 959–66.
- ALTERATIONS OF GRANULOPOIESIS FOLLOWING CHEMOTHERAPY
  GREENBER, P., Bax, I., MARA, B., & Schrier, S. (1974). ALTERATIONS OF GRANULOPOIESIS FOLLOWING CHEMOTHERAPY. BLOOD, 44(3), 375–83.
- Myelodysplastic syndromes: clinical practice guidelines in oncology.
  Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., … Naganuma, M. (2013). Myelodysplastic syndromes: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 11(7), 838–874.
- A 2-gene classifier for predicting response to the famesyltransferase inhibitor tipifarnib in acute myeloid leukemia
  Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., … Karp, J. E. (2008). A 2-gene classifier for predicting response to the famesyltransferase inhibitor tipifarnib in acute myeloid leukemia. BLOOD, 111(5), 2589–96.
- Specific plasma autoantibody reactivity in myelodysplastic syndromes
  Mias, G. I., Chen, R., Zhang, Y., Sridhar, K., Sharon, D., Xiao, L., … Greenberg, P. L. (2013). Specific plasma autoantibody reactivity in myelodysplastic syndromes. Scientific Reports , 3.
- Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
  Zeidan, A. M., Lee, J.-W., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., … Gore, S. D. (2014). Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. BRITISH JOURNAL OF HAEMATOLOGY, 166(3), 352–59.
- Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.
  Johnson, R. C., Kurzer, J. H., Greenberg, P. L., & Gratzinger, D. (2014). Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival. American Journal of Clinical Pathology, 142(6), 795–802.
- Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
  Zeidan, A. M., Lee, J.-W., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., … Gore, S. D. (2014). Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. BRITISH JOURNAL OF HAEMATOLOGY, 167(1), 62–68.
- Mesenchymal Stromal Cell Density is Increased in Higher Grade Myelodysplastic Syndromes and Independently Predicts Survival.
  Johnson, R., Kurzer, J., Greenberg, P., & Gratzinger, D. (2014). Mesenchymal Stromal Cell Density is Increased in Higher Grade Myelodysplastic Syndromes and Independently Predicts Survival. . J Clin Path, 142.
- TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR - CLINICAL AND MARROW HEMATOPOIETIC RESPONSES
  Greenberg, P., Negrin, R., Nagler, A., & Souza, L. (1990). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR - CLINICAL AND MARROW HEMATOPOIETIC RESPONSES. Presented at the SYMP ON HEMATOPOIESIS, TAMARRON,CO,CO,CO: WILEY-LISS, INC.
- Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study
  Deeg, H. J., Gotlib, J., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., … Greenberg, P. (2002). Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study. LEUKEMIA, 16(2), 162–64.
- MURINE GRANULOPOIESIS AFTER FRACTIONATED TOTAL LYMPHOID IRRADIATION AND ALLOGENEIC BONE-MARROW TRANSPLANTATION
  Feiner, R. H., Strober, S., & Greenberg, P. L. (1983). MURINE GRANULOPOIESIS AFTER FRACTIONATED TOTAL LYMPHOID IRRADIATION AND ALLOGENEIC BONE-MARROW TRANSPLANTATION. EXPERIMENTAL HEMATOLOGY, 11(5), 410–17.
- Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
  Valent, P., Horny, H.-P., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P., … Wells, D. A. (2007). Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. LEUKEMIA RESEARCH, 31(6), 727–36.
- Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
  Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., … Dreyfus, F. (2008). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. BLOOD, 111(2), 574–82.
- THE EFFECTS OF RECOMBINANT INTERLEUKIN-2-ACTIVATED NATURAL-KILLER CELLS ON AUTOLOGOUS PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITORS
  Nagler, A., Greenberg, P. L., Lanier, L. L., & Phillips, J. H. (1988). THE EFFECTS OF RECOMBINANT INTERLEUKIN-2-ACTIVATED NATURAL-KILLER CELLS ON AUTOLOGOUS PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITORS. JOURNAL OF EXPERIMENTAL MEDICINE, 168(1), 47–54.
- New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
  Schanz, J., Tuechler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., … Haase, D. (2012). New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. JOURNAL OF CLINICAL ONCOLOGY, 30(8), 820–29.
- Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
  Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., & Barrett, J. (2008). Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 2505–11.
- Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34(+)FISH:results from a German diagnostic study in comparison with an international control group
  Braulke, F., Platzbecker, U., Mueller-Thomas, C., Goetze, K., Germing, U., Bruemmendorf, T. H., … Schanz, J. (2015). Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34(+)FISH:results from a German diagnostic study in comparison with an international control group. HAEMATOLOGICA, 100(2), 205–13.
- Monosomal karyotype in MDS: explaining the poor prognosis?
  Schanz, J., Tuechler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., … Haase, D. (2013). Monosomal karyotype in MDS: explaining the poor prognosis? LEUKEMIA, 27(10), 1988–95.
- MDS prognostic scoring systems - Past, present, and future
  Jonas, B. A., & Greenberg, P. L. (2015). MDS prognostic scoring systems - Past, present, and future. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 28(1), 3–13.
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
  Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., … Tallman, M. S. (2014). Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. JOURNAL OF CLINICAL ONCOLOGY, 32(12), 1242-?
- A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine
  Greenberg, P. L., Garcia-Manero, G., Moore, M., Damon, L., Roboz, G., Hu, K., … Franklin, J. (2013). A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. LEUKEMIA & LYMPHOMA, 54(2), 321–28.
- Prognostic factors and scoring systems in myelodysplastic syndromes
  Sanz, G. F., Sanz, M. A., & Greenberg, P. L. (1998). Prognostic factors and scoring systems in myelodysplastic syndromes. HAEMATOLOGICA, 83(4), 358–68.
- Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
  Kantarjian, H. M., Giles, F. J., Greenberg, P. L., Paquette, R. L., Wang, E. S., Gabrilove, J. L., … Berger, D. P. (2010). Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. BLOOD, 116(17), 3163–70.
- Myelodysplastic Syndromes, Version 2.2015
  Greenberg, P. L., Stone, R. M., Bejar, R., Bennett, J. M., Bloomfield, C. D., Borate, U., … Smith, C. (2015). Myelodysplastic Syndromes, Version 2.2015. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(3), 261–72.
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
  Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., … Kantarjian, H. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. BLOOD, 108(2), 419–25.
- Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes
  Greenberg, P. L. (2015). Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes . J Nat Compr Canc Network , 13(7).
- GRANULOCYTE-MONOCYTE AND GRANULOCYTE-COLONY STIMULATING FACTORS IN MYELODYSPLASTIC SYNDROMES
  Nagler, A., & Greenberg, P. L. (1991). GRANULOCYTE-MONOCYTE AND GRANULOCYTE-COLONY STIMULATING FACTORS IN MYELODYSPLASTIC SYNDROMES. LEUKEMIA & LYMPHOMA, 5(4), 219–30.
- NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.
  Greenberg, P. L., Rigsby, C. K., Stone, R. M., Deeg, H. J., Gore, S. D., Millenson, M. M., … Kumar, R. (2009). NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network , 7, S1–16.
- Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
  Della Porta, M. G., Tuechler, H., Malcovati, L., Schanz, J., Sanz, G., Garcia-Manero, G., … Cazzola, M. (2015). Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia, 29(7), 1502–13.
- Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
  Silverman, L. R., Greenberg, P., Raza, A., Olnes, M. J., Holland, J. F., Reddy, P., … Wilhelm, F. (2015). Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. HEMATOLOGICAL ONCOLOGY, 33(2), 57–66.
- The anemia of chronic disorders due to renal cell carcinoma: ferrokinetic and morphologic documentation of its surgical correction.
  Greenberg, P. L., & CREGER, W. P. (1971). The anemia of chronic disorders due to renal cell carcinoma: ferrokinetic and morphologic documentation of its surgical correction. The American Journal of the Medical Sciences, 261(5), 265–269.
- Cytotoxic effects of cytosine arabinoside and 6-thioguanine in vitro on granulocytic progenitor cells
  Greenberg, P. L., VanKersen, I., & Mosny, S. (1976). Cytotoxic effects of cytosine arabinoside and 6-thioguanine in vitro on granulocytic progenitor cells. Cancer Res .
- DENSITY DISTRIBUTION PATTERNS OF MARROW COLONY-FORMING CELLS DURING REMISSION OF ACUTE MYELOGENOUS LEUKEMIA
  Heller, P., & Greenberg, P. (1977). DENSITY DISTRIBUTION PATTERNS OF MARROW COLONY-FORMING CELLS DURING REMISSION OF ACUTE MYELOGENOUS LEUKEMIA. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 59(2), 313–16.
- PRELEUKEMIC SYNDROME - CORRELATION OF INVITRO PARAMETERS OF GRANULOPOIESIS WITH CLINICAL-FEATURES
  Greenberg, P. L., & MARA, B. (1979). PRELEUKEMIC SYNDROME - CORRELATION OF INVITRO PARAMETERS OF GRANULOPOIESIS WITH CLINICAL-FEATURES. AMERICAN JOURNAL OF MEDICINE, 66(6), 951–58.
- MARROW ADHERENT CELL COLONY-STIMULATING ACTIVITY PRODUCTION IN ACUTE MYELOID-LEUKEMIA
  Greenberg, P. L., MARA, B., & Heller, P. (1978). MARROW ADHERENT CELL COLONY-STIMULATING ACTIVITY PRODUCTION IN ACUTE MYELOID-LEUKEMIA. BLOOD, 52(2), 362–78.
- EXPRESSION OF EVI1 IN MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES WITHOUT 3Q26 TRANSLOCATIONS
  Russell, M., List, A., Greenberg, P., Woodward, S., Glinsmann, B., Parganas, E., … Taetle, R. (1994). EXPRESSION OF EVI1 IN MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES WITHOUT 3Q26 TRANSLOCATIONS. BLOOD, 84(4), 1243–48.
- DIVERGENT PATTERNS OF MARROW CELL-SUSPENSION CULTURE GROWTH IN MYELOID LEUKEMIAS - CORRELATION OF INVITRO FINDINGS WITH CLINICAL FEATURES
  Elias, L., & Greenberg, P. (1977). DIVERGENT PATTERNS OF MARROW CELL-SUSPENSION CULTURE GROWTH IN MYELOID LEUKEMIAS - CORRELATION OF INVITRO FINDINGS WITH CLINICAL FEATURES. BLOOD, 50(2), 263–74.
- ALTERATION OF COLONY-STIMULATING FACTOR OUTPUT, ENDOTOXEMIA, AND GRANULOPOIESIS IN CYCLIC NEUTROPENIA
  Greenberg, P. L., Bax, I., Levin, J., & Andrews, T. M. (1976). ALTERATION OF COLONY-STIMULATING FACTOR OUTPUT, ENDOTOXEMIA, AND GRANULOPOIESIS IN CYCLIC NEUTROPENIA. AMERICAN JOURNAL OF HEMATOLOGY, 1(4), 375–85.
- CORRELATIVE PATTERNS OF LEUKOCYTE COUNTS AT PRESENTATION AND RELAPSE IN ACUTE MYELOGENOUS LEUKEMIA
  Schwartz, R. S., MacKintosh, F. R., & Greenberg, P. L. (1986). CORRELATIVE PATTERNS OF LEUKOCYTE COUNTS AT PRESENTATION AND RELAPSE IN ACUTE MYELOGENOUS LEUKEMIA. ACTA HAEMATOLOGICA, 75(2), 79–82.
- STROMAL COLONY-STIMULATING ACTIVITY PRODUCTION AND MYELOID COLONY-FORMING CELLS IN HUMAN HEMATOPOIETIC AND NON-HEMATOPOIETIC BONE-MARROW
  Schwartz, R. S., & Greenberg, P. L. (1981). STROMAL COLONY-STIMULATING ACTIVITY PRODUCTION AND MYELOID COLONY-FORMING CELLS IN HUMAN HEMATOPOIETIC AND NON-HEMATOPOIETIC BONE-MARROW. BLOOD, 57(4), 771–80.
- CYTOTOXIC EFFECTS OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND 6-THIOGUANINE INVITRO ON GRANULOCYTIC PROGENITOR CELLS
  Greenberg, P. L., VANKERSEN, I., & MOSNY, S. (1976). CYTOTOXIC EFFECTS OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND 6-THIOGUANINE INVITRO ON GRANULOCYTIC PROGENITOR CELLS. CANCER RESEARCH, 36(12), 4412–17.
- CYTOTOXIC EFFECTS OF INTERFERON INVITRO ON GRANULOCYTIC PROGENITOR CELLS
  Greenberg, P. L., & MOSNY, S. A. (1977). CYTOTOXIC EFFECTS OF INTERFERON INVITRO ON GRANULOCYTIC PROGENITOR CELLS. CANCER RESEARCH, 37(6), 1794–99.
- SPLENIC GRANULOCYTOPOIESIS AND PRODUCTION OF COLONY-STIMULATING ACTIVITY IN LYMPHOMA AND LEUKEMIA
  Greenberg, P. L., & STEED, S. M. (1981). SPLENIC GRANULOCYTOPOIESIS AND PRODUCTION OF COLONY-STIMULATING ACTIVITY IN LYMPHOMA AND LEUKEMIA. BLOOD, 57(1), 119–29.
- CLINICAL RELEVANCE OF INVITRO STUDY OF GRANULOCYTOPOIESIS
  Greenberg, P. L. (1980). CLINICAL RELEVANCE OF INVITRO STUDY OF GRANULOCYTOPOIESIS. SCANDINAVIAN JOURNAL OF HAEMATOLOGY, 25(5), 369–81.
- CHARACTERIZATION OF ANTIGENIC DETERMINANTS ON HUMAN MYELOID COLONY-FORMING CELLS WITH MONOCLONAL-ANTIBODIES
  Greenberg, P., Grossman, M., Charron, D., & Levy, R. (1981). CHARACTERIZATION OF ANTIGENIC DETERMINANTS ON HUMAN MYELOID COLONY-FORMING CELLS WITH MONOCLONAL-ANTIBODIES. EXPERIMENTAL HEMATOLOGY, 9(7), 781–87.
- THE SMOLDERING MYELOID LEUKEMIC STATES - CLINICAL AND BIOLOGIC FEATURES
  Greenberg, P. L. (1983). THE SMOLDERING MYELOID LEUKEMIC STATES - CLINICAL AND BIOLOGIC FEATURES. BLOOD, 61(6), 1035–44.
- RESPONSE OF AGRANULOCYTOSIS TO PROLONGED ANTI-THYMOCYTE GLOBULIN THERAPY
  CHUDWIN, D. S., Cowan, M. J., Greenberg, P. L., Wara, D. W., & Ammann, A. J. (1983). RESPONSE OF AGRANULOCYTOSIS TO PROLONGED ANTI-THYMOCYTE GLOBULIN THERAPY. JOURNAL OF PEDIATRICS, 103(2), 223–27.
- HUMAN SPLEEN-CELL GENERATION OF FACTORS STIMULATING HUMAN PLURIPOTENT STEM-CELL, ERYTHROID, AND MYELOID PROGENITOR-CELL GROWTH
  Fabian, I., Douer, D., Levitt, L., Kletter, Y., & Greenberg, P. L. (1985). HUMAN SPLEEN-CELL GENERATION OF FACTORS STIMULATING HUMAN PLURIPOTENT STEM-CELL, ERYTHROID, AND MYELOID PROGENITOR-CELL GROWTH. BLOOD, 65(4), 990–96.
- 13-CIS RETINOIC ACID TREATMENT FOR MYELODYSPLASTIC SYNDROMES
  Picozzi, V. J., SWANSON, G. F., Morgan, R., Hecht, F., & Greenberg, P. L. (1986). 13-CIS RETINOIC ACID TREATMENT FOR MYELODYSPLASTIC SYNDROMES. JOURNAL OF CLINICAL ONCOLOGY, 4(4), 589–95.
- RESPONSES OF HEMATOPOIETIC PRECURSORS TO 13-CIS RETINOIC ACID AND 1,25 DIHYDROXYVITAMIN-D3 IN THE MYELODYSPLASTIC SYNDROMES
  Swanson, G., Picozzi, V., Morgan, R., Hecht, F., & Greenberg, P. (1986). RESPONSES OF HEMATOPOIETIC PRECURSORS TO 13-CIS RETINOIC ACID AND 1,25 DIHYDROXYVITAMIN-D3 IN THE MYELODYSPLASTIC SYNDROMES. BLOOD, 67(4), 1154–61.
- BIOLOGIC ABNORMALITIES IN THE MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE DISORDERS
  Greenberg, P. L. (1986). BIOLOGIC ABNORMALITIES IN THE MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE DISORDERS. ACTA HAEMATOLOGICA JAPONICA, 49(8), 1509–27.
- CHARACTERIZATION OF THE INVITRO STROMAL MICROENVIRONMENT OF HUMAN-BONE MARROW
  Strobel, E. S., GAY, R. E., & Greenberg, P. L. (1986). CHARACTERIZATION OF THE INVITRO STROMAL MICROENVIRONMENT OF HUMAN-BONE MARROW. INTERNATIONAL JOURNAL OF CELL CLONING, 4(5), 341–56.
- ROLE OF INTRACELLULAR DEGRADATION OF EPIDERMAL GROWTH-FACTOR IN MITOGENESIS
  Greenberg, P. L., & ROZENGURT, E. (1982). ROLE OF INTRACELLULAR DEGRADATION OF EPIDERMAL GROWTH-FACTOR IN MITOGENESIS. EXPERIMENTAL CELL RESEARCH, 142(1), 111–17.
- Chronic myelogenous leukemia.
  O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., … Wetzler, M. (2005). Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network , 3(6), 732–755.
- Intramedullary influences on in vitro granulopoiesis in human acute myeloid leukemia.
  Greenberg, P., & MARA, B. (1979). Intramedullary influences on in vitro granulopoiesis in human acute myeloid leukemia. Haematology and Blood Transfusion, 23, 199–204.
- Chronic myelogenous leukemia.
  O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., … Wetzler, M. (2007). Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network , 5(5), 474–496.
- Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
  Platzbecker, U., Wong, R. S. M., Verma, A., Abboud, C., Araujo, S., Chiou, T.-J., … Giagounidis, A. (2015). Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. LANCET HAEMATOLOGY, 2(10), E417–E426.
- The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
  Maxson, J. E., Luty, S. B., Macmaniman, J. D., Paik, J. C., Gotlib, J., Greenberg, P., … Tyner, J. W. (2016). The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clinical Cancer Research , 22(3), 757–64.
- Frequency of del(12p) is Commonly Underestimated in Myelodysplastic Syndromes: Results from a German Diagnostic Study in Comparison with an International Control Group
  Braulke, F., Mueller-Thomas, C., Goetze, K., Platzbecker, U., Germing, U., Hofmann, W.-K., … Schanz, J. (2015). Frequency of del(12p) is Commonly Underestimated in Myelodysplastic Syndromes: Results from a German Diagnostic Study in Comparison with an International Control Group. GENES CHROMOSOMES & CANCER, 54(12), 809–17.
- Update on Myelodysplastic Syndromes Classification and Prognosis.
  Gratzinger, D., & Greenberg, P. L. (2013). Update on Myelodysplastic Syndromes Classification and Prognosis. Surgical Pathology Clinics, 6(4), 693–728.
- Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
  Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. LEUKEMIA & LYMPHOMA, 57(3), 609–15.
- Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
  Prebet, T., Sun, Z., Ketterling, R. P., Zeidan, A., Greenberg, P., Herman, J., … Gore, S. D. (2016). Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. British Journal of Haematology, 172(3), 384–91.
- Immune checkpoint pathways: perspectives on myeloid malignancies
  Rivera, G. A., Behbahan, I. S., & Greenberg, P. L. (2016). Immune checkpoint pathways: perspectives on myeloid malignancies. LEUKEMIA & LYMPHOMA, 57(5), 995–1001.
- Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
  Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., … Silverman, L. R. (2016). Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. LANCET ONCOLOGY, 17(4), 496–508.
- KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
  Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., … Lancet, J. E. (2016). KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leukemia Research, 50, 123–31.
- Time-dependent changes in mortality and transformation risk in MDS.
  Pfeilstöcker, M., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Solé, F., … Greenberg, P. L. (2016). Time-dependent changes in mortality and transformation risk in MDS. Blood, 128(7), 902–10.
- Myelodysplastic Syndromes
  Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., … Westervelt, P. (2011). Myelodysplastic Syndromes. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(1), 30–56.
- Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
  Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., … Haase, D. (2016). Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood.
- Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis
  Park, S., Fenaux, P., Greenberg, P., Mehta, B., Callaghan, F., Kim, C., … Xu, H. (2016). Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. BRITISH JOURNAL OF HAEMATOLOGY, 174(5), 730–47.
- The Impact of Somatic and Germline Mutations in MDS and Related Disorders
  Bejar, R., & Greenberg, P. L. (2017). The Impact of Somatic and Germline Mutations in MDS and Related Disorders . J Nat Comp Canc Network , 15.
- ABNORMAL INVITRO CLONAL GROWTH-PATTERNS IN THE MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES - RESPONSES TO RETINOIC ACID AND VITAMIN-D
  Greenberg, P. (1986). ABNORMAL INVITRO CLONAL GROWTH-PATTERNS IN THE MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES - RESPONSES TO RETINOIC ACID AND VITAMIN-D. ACTA HAEMATOLOGICA JAPONICA, 49(2), 181–81.
- THE ROLE OF HEMATOPOIETIC GROWTH-FACTORS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
  Greenberg, P. (1995). THE ROLE OF HEMATOPOIETIC GROWTH-FACTORS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES. GEMATOLOGIYA I TRANSFUZIOLOGIYA, 40(2), 12–13.
- REMISSION OF ACUTE MYELOGENOUS LEUKEMIA COMPLICATING WALDENSTROM MACROGLOBULINEMIA
  EFFRON, M. K., Rosenbaum, J., & Greenberg, P. L. (1978). REMISSION OF ACUTE MYELOGENOUS LEUKEMIA COMPLICATING WALDENSTROM MACROGLOBULINEMIA. WESTERN JOURNAL OF MEDICINE, 129(4), 337–39.
- Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology
  Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M., … Smith, C. (2017). Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(1), 60–87.
- Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age
  Atallah, E., Horowitz, M. M., Logan, B., Chen, M., Boo, M. J., Cutler, C. S., … Rizzo, J. D. (2015). Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. BLOOD, 126(23).
- Distinct Transcriptomic and Exomic Abnormalities Within Myelodysplastic Syndrome Marrow Cells
  Im, H., Rao, V., Sridhar, K., Bentley, J., Mishra, T., Chen, R., … Greenberg, P. L. (2018). Distinct Transcriptomic and Exomic Abnormalities Within Myelodysplastic Syndrome Marrow Cells. Leukemia & Lymphoma.
- Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
  Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D., Malcovati, L., … Bennett, J. M. (2017). Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. ONCOTARGET, 8(43), 73483–500.
- CHROMOSOMAL ABERRATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - RELATIONS TO PRIMARY DISEASE, THERAPY AND PROGNOSTIC SIGNIFICANCE
  Nomdedeu, M., Tuechler, H., Kuendgen, A., Sole, F., Schanz, J., Hildebrandt, B., … Haase, D. (2017). CHROMOSOMAL ABERRATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - RELATIONS TO PRIMARY DISEASE, THERAPY AND PROGNOSTIC SIGNIFICANCE. LEUKEMIA RESEARCH, 55, S32–S33.
- p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study
  Saft, L., Li, J. S., Greenberg, P. L., Sekeres, M. A., Sanz, G. F., Dreyfus, F., … Hellstrom-Lindberg, E. (2014). p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study. BLOOD, 124(21).
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
  Tefferi, A., Rajkumar, S. V., Gertz, M. A., Kyle, R. A., Kantarjian, H., Allison, J., … Wiernik, P. H. (2015). In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. MAYO CLINIC PROCEEDINGS, 90(8), 996–1000.
- A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
  Gerds, A. T., Scott, B. L., Greenberg, P., Verma, A., Phuong, P., Yan, M., … Donnellan, W. (2017). A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES. HAEMATOLOGICA, 102, 262.
- Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
  Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mittelman, M., Muus, P., … List, A. F. (2017). Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). JOURNAL OF HEMATOLOGY & ONCOLOGY, 10, 131.
- The classical nature of distinctive CMML monocytes
  Greenberg, P. L. (2017). The classical nature of distinctive CMML monocytes. BLOOD, 129(13), 1745–46.
- Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
  Garcia-Manero, G., Fenaux, P., Al-Kali, A., Navada, S. C., Baer, M. R., Raza, A., … Silverman, L. R. (2016). Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). BLOOD, 128(22).
- Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)
  Kuendgen, A., Tuechler, H., Nomdedeu, M., Haase, D., Garcia-Manero, G., Komrokji, R. S., … Sanz, G. (2016). Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). BLOOD, 128(22).
- Single-cell network profiling (SCNP) to evaluate the proteomic profiles associated with ON 01910.Na treatment of MDS patients (Pts)
  Cesano, A., Soper, D., Banville, S., Mai Tran, Seetharam, M., Kumar, R., … Greenberg, P. (2011). Single-cell network profiling (SCNP) to evaluate the proteomic profiles associated with ON 01910.Na treatment of MDS patients (Pts). CANCER RESEARCH, 71.
- Nano-scale phospho-proteomic analysis to define diagnostic signatures and biomarkers of therapeutic activity in cancer
  Fan, A. C., Banerjee, P., Xu, L., Kong, C., Sabatti, C., Wilheim, F., … Felsher, D. W. (2012). Nano-scale phospho-proteomic analysis to define diagnostic signatures and biomarkers of therapeutic activity in cancer. CANCER RESEARCH, 72.
- RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)
  Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., … Silverman, L. R. (2015). RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). LEUKEMIA RESEARCH, 39, S57–S58.
- BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?
  Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., … Garcia-Manero, G. (2015). BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION? LEUKEMIA RESEARCH, 39, S44–S45.
- Cytogenetic classification according to IPSS/-R is possible from peripheral blood in patients with Myelodysplastic Syndromes
  Braulke, F., Platzbecker, U., Mueller-Thomas, C., Goetze, K., Germing, U., Bruemmerndorf, T. H., … Schanz, J. (2016). Cytogenetic classification according to IPSS/-R is possible from peripheral blood in patients with Myelodysplastic Syndromes. ONCOLOGY RESEARCH AND TREATMENT, 39, 171.
- Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee
  Bejar, R., Papaemmanuil, E., Haferlach, T., Garcia-Manero, G., Maciejewski, J. P., Sekeres, M. A., … Ebert, B. L. (2015). Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. BLOOD, 126(23).
- An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)
  Kuendgen, A., Tuechler, H., Nomdedeu, M., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., … Sanz, G. (2015). An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). BLOOD, 126(23).
- Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes
  Schanz, J., Tuechler, H., Sole, F., Sanz, G., Garcia-Manero, G., Le Beau, M. M., … Haase, D. (2015). Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. BLOOD, 126(23).
- Underestimation of 12p-deletion in myelodysplastic syndromes? Results from a German diagnostic study in comparison with an international control group
  Braulke, F., Mueller-Thomas, C., Goetze, K., Platzbecker, U., Germing, U., Hofmann, W.-K., … Schanz, J. (2015). Underestimation of 12p-deletion in myelodysplastic syndromes? Results from a German diagnostic study in comparison with an international control group. Oncology Research and Treatment, 38, 33.
- Prognostic significance of rare single abnormalities in Myelodysplastic Syndromes
  Schanz, J., Tuechler, H., Sole, F., Sanz, G., Garcia-Manero, G., LeBeau, M., … Haase, D. (2015). Prognostic significance of rare single abnormalities in Myelodysplastic Syndromes. Oncology Research and Treatment, 38, 31.
- PROGNOSTIC AND PREDICTIVE VALUE OF IPSS-R IN ASSESSING OVERALL SURVIVAL (OS) IN A PHASE III STUDY OF RIGOSERTIB IN SECOND-LINE HIGHER-RISK (HR) MDS PATIENTS
  Silverman, L., Fenaux, P., Al-Kali, A., Baer, M., Sekeres, M., Roboz, G., … Garcia-Manero, G. (2015). PROGNOSTIC AND PREDICTIVE VALUE OF IPSS-R IN ASSESSING OVERALL SURVIVAL (OS) IN A PHASE III STUDY OF RIGOSERTIB IN SECOND-LINE HIGHER-RISK (HR) MDS PATIENTS. HAEMATOLOGICA, 100, 492.
- CORRELATION OF OVERALL SURVIVAL (OS) WITH BONE MARROW BLAST (BMBL) RESPONSE IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS)
  Silverman, L., Fenaux, P., Greenberg, P., Demakos, E., Santini, V., Seymour, J., … Garcia-Manero, G. (2015). CORRELATION OF OVERALL SURVIVAL (OS) WITH BONE MARROW BLAST (BMBL) RESPONSE IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS). HAEMATOLOGICA, 100, 242.
- OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED, CONTROLLED, PHASE III STUDY OF RIGOSERTIB
  Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M., Sekeres, M., Roboz, G., … Silverman, L. (2015). OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED, CONTROLLED, PHASE III STUDY OF RIGOSERTIB. HAEMATOLOGICA, 100, 238.
- Evaluation of hematopoietic stem/progenitor cells in MDS reveals novel pathogenic mechanisms
  Park, C. Y., Pang, W. W., Chung, S. S., Pluvinage, J. V., Price, E. A., Sridhar, K., … Weissman, I. L. (2013). Evaluation of hematopoietic stem/progenitor cells in MDS reveals novel pathogenic mechanisms. LEUKEMIA RESEARCH, 37, S12–S13.
- Revised International Prognostic Scoring System (IPSS-R) for MDS: Update
  Greenberg, P., & Tuechler, H. (2013). Revised International Prognostic Scoring System (IPSS-R) for MDS: Update. LEUKEMIA RESEARCH, 37, S3.
- IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
  Barreyro, L., Mitchell, K., Will, B., Bartholdy, B., Zhou, L., Todorova, T., … Steidl, U. (2013). IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MOLECULAR CANCER THERAPEUTICS, 12(11).
- Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.
  Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., … Garcia-Manero, G. (2015). Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
  Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., … Garcia-Manero, G. (2015). Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome
  Silverman, L. R., Fenaux, P., Greenberg, P., Demakos, E. P., Santini, V., Seymour, J. F., … Garcia-Manero, G. (2015). Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
- Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)
  Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., … Garcia-Manero, G. (2014). Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). BLOOD. AMER SOC HEMATOLOGY.
- Profiling Myelodysplastic Syndromes By Mass Cytometry Demonstrates Distinct Immunophenotypic Aberrancies in Stem and Progenitor Populations
  Behbehani, G. K., Finck, R., Samusik, N., Gherardini, P. F., Sridhar, K. J., Fantl, W. J., … Nolan, G. P. (2014). Profiling Myelodysplastic Syndromes By Mass Cytometry Demonstrates Distinct Immunophenotypic Aberrancies in Stem and Progenitor Populations. BLOOD, 124(21).
- Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype
  Mallo, M., Tuechler, H., Shih, L.-Y., Ogawa, S., Sanada, M., Lin, T.-L., … Sole, F. (2014). Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype. BLOOD, 124(21).
- Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
  Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., … Silverman, L. R. (2014). Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). BLOOD. AMER SOC HEMATOLOGY.
- Transcriptomic Evaluation of CD34+Marrow Cells from Myelodysplastic Syndrome (MDS) Patients
  Im, H., Rao, V., Sridhar, K. J., Chen, R., Mias, G., Zhang, Y., … Greenberg, P. L. (2014). Transcriptomic Evaluation of CD34+Marrow Cells from Myelodysplastic Syndrome (MDS) Patients. BLOOD, 124(21).
- KB004, a Novel Non-Fucosylated Humaneered (R) Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies
  Swords, R. T., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., … Lancet, J. E. (2014). KB004, a Novel Non-Fucosylated Humaneered (R) Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies. BLOOD, 124(21).
- TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee
  Bejar, R., Papaemmanuil, E., Haferlach, T., Garcia-Manero, G., Maciejewski, J. P., Sekeres, M. A., … Ebert, B. L. (2014). TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. BLOOD, 124(21).
- MYELODYSPLASTIC SYNDROMES: OLD AND NEW CLASSIFICATION AND PROGNOSTIC SYSTEMS
  Greenberg, P. (2014). MYELODYSPLASTIC SYNDROMES: OLD AND NEW CLASSIFICATION AND PROGNOSTIC SYSTEMS. LEUKEMIA RESEARCH, 38, S4.
- Is IPSS/IPSS-R cytogenetic classification possible from peripheral blood in MDS patients? Comparative results from a prospective German diagnostic study with the data set of an international collaboration
  Braulke, F., Platzbecker, U., Mueller-Thomas, C., Goetze, K., Germing, U., Bruemmendorf, T. H., … Schanz, J. (2014). Is IPSS/IPSS-R cytogenetic classification possible from peripheral blood in MDS patients? Comparative results from a prospective German diagnostic study with the data set of an international collaboration. ONCOLOGY RESEARCH AND TREATMENT, 37, 235–36.
- Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM
  Sekeres, M., Ades, L., Tuechler, H., Sanz, G., Levis, A., Malcovati, L., … Greenberg, P. (2013). Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM. LEUKEMIA RESEARCH, 37, S74–S75.
- Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
  Sekeres, M. A., Swern, A. S., Fenaux, P., Greenberg, P. L., Sanz, G. F., Bennett, J. M., … Sugrue, M. M. (2014). Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). BLOOD CANCER JOURNAL, 4, e242.
- Application of the French prognostic score (FPS) to assess overall survival (OS) in a US-based cohort of patients (pts) treated with azacitidine (Aza).
  Zeidan, A., Sun, Z., Prebet, T., Greenberg, P., Juckett, M., Smith, M. R., … Tallman, M. S. (2013). Application of the French prognostic score (FPS) to assess overall survival (OS) in a US-based cohort of patients (pts) treated with azacitidine (Aza). JOURNAL OF CLINICAL ONCOLOGY, 31(15).
- Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis
  Sekeres, M., Swern, A., Fenaux, P., Greenberg, P., Sanz, G., Bennett, J., … Sugrue, M. (2013). Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis. LEUKEMIA RESEARCH, 37, S69–S70.
- Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q
  Fenaux, P., Guerci-Bresler, A., Muus, P., Sekeres, M. A., Giagounidis, A., Deeg, H. J., … List, A. F. (2012). Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- Randomized, dose-escalation study of the p38 alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
  Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M. A., Parmar, S., Greenberg, P., … List, A. F. (2013). Randomized, dose-escalation study of the p38 alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. LEUKEMIA, 27(4), 977–80.
- Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival
  Raza, A., Greenberg, P. L., Olnes, M. J., Silverman, L. R., & Wilhelm, F. (2011). Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival. BLOOD, 118(21), 1633.
- Do Erythropoiesis-Stimulating Agents (ESAs) Affect Survival in Anemic Patients with Myelodysplastic Syndromes (MDS)?
  Davidoff, A. J., Ke, X., Baer, M. R., Smith, S. R. W., Zandberg, D., Hendrick, F., … Gore, S. D. (2011). Do Erythropoiesis-Stimulating Agents (ESAs) Affect Survival in Anemic Patients with Myelodysplastic Syndromes (MDS)? BLOOD, 118(21), 1204–5.
- A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS
  Koreth, J., Pidala, J., Perez, W. S., Deeg, H. J., Garcia-Manero, G., Malcovati, L., … Cutler, C. S. (2011). A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. BLOOD, 118(21), 56–57.
- Characterization and prognostic significance of cytogenetically unrelated clones in myelodysplastic syndromes and acute myeloid leukemia
  Schanz, J., Kessels, S., Haferlach, C., Bardi, G., Gourgouveli, E., Slovak, M. L., … Haase, D. (2011). Characterization and prognostic significance of cytogenetically unrelated clones in myelodysplastic syndromes and acute myeloid leukemia. ONKOLOGIE, 34, 8.
- Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS - Reclassification From Poor to Intermediate Prognosis
  Schanz, J., Tuechler, H., Sole, F., Mallo, M., Hildebrandt, B., Steidl, C., … Haase, D. (2010). Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS - Reclassification From Poor to Intermediate Prognosis. BLOOD, 116(21), 775–76.
- Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia - Characterization and Prognostic Relevance
  Schanz, J., Stephanie, F., Haferlach, C., Bardi, G., Slovak, M. L., Eclache, V., … Haase, D. (2010). Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia - Characterization and Prognostic Relevance. BLOOD, 116(21), 1639.
- A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study
  Prebet, T., Sun, Z., Ketterling, R., Hicks, G., Beach, C. L., Greenberg, P. L., … Gore, S. D. (2010). A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study. BLOOD, 116(21), 1636.
- Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?
  Ganster, C., Braulke, F., Shirneshan, K., Sole, F., Mallo, M., Cervera, J., … Schanz, J. (2010). Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality? BLOOD, 116(21), 1634.
- Overall Survival In Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Treated with On 01910.Na Correlates with Bone Marrow Blast Response.
  Silverman, L. R., Kaza, A., Sloand, E. M., Greenberg, P. L., & Wilhelm, F. E. (2010). Overall Survival In Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Treated with On 01910.Na Correlates with Bone Marrow Blast Response. BLOOD, 116(21), 1629–30.
- Loss of the Y Chromosome in MDS: Clonal abnormality or age-related accident?
  Ganster, C., Schanz, J., Braulke, F., Shimeshan, K., Sole, F., Hildebrandt, B., … Haase, D. (2010). Loss of the Y Chromosome in MDS: Clonal abnormality or age-related accident? ONKOLOGIE, 33, 224.
- Unrelated clones in AML/MDS - characterisation and prognostic relevance
  Fischer, S., Haase, D., Haferlach, C., Bardi, G., Slovak, M., Johansson, B., … Schanz, J. (2010). Unrelated clones in AML/MDS - characterisation and prognostic relevance. ONKOLOGIE, 33, 37.
- PROPOSAL OF A NEW, COMPREHENSIVE CYTOGENETIC SCORING SYSTEM FOR PRIMARY MDS
  Schanz, J., Tuechler, H., Sole, F., Mallo, M., Hildebrandt, B., Slovak, M., … Haase, D. (2010). PROPOSAL OF A NEW, COMPREHENSIVE CYTOGENETIC SCORING SYSTEM FOR PRIMARY MDS. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 219.
- Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.
  Soper, D. M., Huang, Y.-W., Wilhelm, F., Cosenza, S. C., Reddy, E. P., Cesano, A., … Fantl, W. J. (2009). Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound. BLOOD, 114(22), 1472–73.
- Cytogenetic Risk Features in MDS-Update and Present State.
  Schanz, J., Tuechler, H., Sole, F., Mallo, M., Hildebrandt, B., Slovak, M. L., … Haase, D. (2009). Cytogenetic Risk Features in MDS-Update and Present State. BLOOD, 114(22), 1084.
- Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine
  Greenberg, P. L., Garcia-Manero, G., Moore, M. R., Damon, L. E., Roboz, G. J., Wei, H., … Franklin, J. L. (2009). Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine. BLOOD. AMER SOC HEMATOLOGY.
- Safety of Deferasirox (Exjade (R)) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function
  Schmid, M., Cappellini, M. D., Porter, J. B., Greenberg, P. L., Lawniczek, T., Glaser, S., … Gattermann, N. (2009). Safety of Deferasirox (Exjade (R)) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function. BLOOD, 114(22), 702–3.
- Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (Exjade (R)) therapy in a cohort of patients with MDS
  Greenberg, P. L., Koller, C. A., Glynos, T., Paley, C., & Schiffer, C. (2009). Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (Exjade (R)) therapy in a cohort of patients with MDS. LEUKEMIA RESEARCH, 33, S120.
- Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine
  Kantarjian, H., Giles, F., Greenberg, P., Paquette, R., Wang, E., Gabrilove, J., … Franklin, J. (2008). Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine. BLOOD, 112(11), 89–90.
- Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
  Miyazaki, Y., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Sole, F., … Greenberg, P. L. (2018). Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. LEUKEMIA RESEARCH, 73, 51–57.
- Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance
  Schanz, J., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., … Haase, D. (2018). Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. GENES CHROMOSOMES & CANCER, 57(11), 547–56.
- Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse
  Aleshin, A., Durruthy-Durruthy, R., Medeiros, B. C., Eastburn, D. J., & Greenberg, P. L. (2018). Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse. BLOOD, 132.
- PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis
  Gerds, A. T., Scott, B. L., Greenberg, P. L., Khaled, S. K., Lin, T. L., Pollyea, D. A., … Donnellan, W. B. (2018). PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. BLOOD, 132.
- A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
  Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., … Karp, J. E. (2007). A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. BLOOD. AMER SOC HEMATOLOGY.
- Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC).
  Advani, R., Saba, H. I., Tallman, M., Rowe, J. M., Wiernik, P. H., Ramek, J., … Greenberg, P. (1997). Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). BLOOD, 90(10), 2260.
- GRANULOCYTE DIFFERENTIATION FACTOR PRODUCTION BY HUMAN MARROW AND BLOOD-CELLS
  GREENBERG, P. L., BAKER, S. J., FOK, W. Y., FOUNG, S. K., & ENGLEMAN, E. G. (1984). GRANULOCYTE DIFFERENTIATION FACTOR PRODUCTION BY HUMAN MARROW AND BLOOD-CELLS. EXPERIMENTAL HEMATOLOGY, 12(6), 370.
- BIOLOGIC RATHER THAN MORPHOLOGIC MARKERS IN MYELODYSPLASTIC SYNDROMES
  GREENBERG, P., & BAGBY, G. (1983). BIOLOGIC RATHER THAN MORPHOLOGIC MARKERS IN MYELODYSPLASTIC SYNDROMES. BRITISH JOURNAL OF HAEMATOLOGY, 53(3), 532–34.
- TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR
  NEGRIN, R. S., HAEUBER, D. H., NAGLER, A., SOUZA, L. M., & GREENBERG, P. L. (1988). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR. EXPERIMENTAL HEMATOLOGY, 16(6), 519.
- Proposed minimal diagnostic criteria for myelodysplastic syndromes
  Valent, P., Horny, H.-P., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., … Bennett, J. M. (2007). Proposed minimal diagnostic criteria for myelodysplastic syndromes. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 92, 80.
- Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities.
  Raza, A., Reeves, J. E., Feldman, E. J., Deeg, H. J., Dreisbach, L., Schiffer, C. A., … List, A. F. (2006). Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities. BLOOD, 108(11), 78A.
- HIGH-INCIDENCE OF POLYCLONAL GRANULOCYTOPOIESIS IN MYELODYSPLASTIC SYNDROMES (MDS)
  BUSQUE, L., KOHLER, S., DEHART, D., SAXENA, R., BERNSTEIN, S., STONE, R., … GILLILAND, D. G. (1993). HIGH-INCIDENCE OF POLYCLONAL GRANULOCYTOPOIESIS IN MYELODYSPLASTIC SYNDROMES (MDS). BLOOD, 82(10), A196.
- Deferasirox (Exjade (R), ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia
  Greenberg, P., Dine, G., Ganser, A., Verhoef, G., DeBusscher, L., Quarta, G., … Rabault, B. (2005). Deferasirox (Exjade (R), ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia. BLOOD, 106(11), 757A.
- Phase II trial of darbepoetin alfa in myelodysplastic syndrome (MDS): Preliminary efficacy, safety, and in vitro results.
  Gotlib, J., Quesada, S., Bhamidipati, J., Chaudry, K., Sridhar, K., Dugan, K., … Greenberg, P. L. (2004). Phase II trial of darbepoetin alfa in myelodysplastic syndrome (MDS): Preliminary efficacy, safety, and in vitro results. BLOOD, 104(11), 267B–268B.
- ESTIMATION OF THE RELATIONSHIP BETWEEN SERUM FERRITIN AND LIVER IRON CONCENTRATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
  Gattermann, N., Greenberg, P., Urabe, A., El-Ali, A., Martin, N., & Porter, J. (2013). ESTIMATION OF THE RELATIONSHIP BETWEEN SERUM FERRITIN AND LIVER IRON CONCENTRATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. HAEMATOLOGICA, 98, 178.
- Phase I/II study of tipifarnib (ZARNESTRA (TM), farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): Interim results.
  Gotlib, J., Loh, M., Lancet, J. E., Vattikuti, S., Quesada, S., Dugan, K., … Greenberg, P. L. (2003). Phase I/II study of tipifarnib (ZARNESTRA (TM), farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): Interim results. BLOOD. AMER SOC HEMATOLOGY.
- Tipifarnib (ZARNESTRA (TM)) and imatinib (GLEEVEC (TM)) combination therapy in patients with advanced chronic myelogenous leukemia (CML): Preliminary results of a phase I study.
  Gotlib, J., Mauro, M., O'Dwyer, M. E., Fechter, L., Dugan, K., Kuyl, J., … Greenberg, P. L. (2003). Tipifarnib (ZARNESTRA (TM)) and imatinib (GLEEVEC (TM)) combination therapy in patients with advanced chronic myelogenous leukemia (CML): Preliminary results of a phase I study. BLOOD, 102(11), 909A–910A.
- PLACEBO-CONTROLLED, RANDOMIZED, PHASE I/II TRIAL OF THE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG IN THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA
  Platzbecker, U., Wong, R., Verma, A., Abboud, C., Araujo, S., Chiou, T., … Giagounidis, A. (2013). PLACEBO-CONTROLLED, RANDOMIZED, PHASE I/II TRIAL OF THE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG IN THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA, 98, 455.
- Report of an international working group to standardize response criteria for myelodysplastic syndromes
  Cheson, B. D., Bennett, J. M., Kantarjian, H., Pinto, A., Schiffer, C. A., Nimer, S. D., … Greenberg, P. L. (2000). Report of an international working group to standardize response criteria for myelodysplastic syndromes. BLOOD, 96(12), 3671–74.
- Leukemic cell resistance: targeting needed beyond MDR-1
  Greenberg, P. (2003). Leukemic cell resistance: targeting needed beyond MDR-1. BLOOD, 102(4), 1149.
- INVITRO CULTURE TECHNIQUES DEFINING BIOLOGICAL ABNORMALITIES IN THE MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE DISORDERS
  GREENBERG, P. L. (1986). INVITRO CULTURE TECHNIQUES DEFINING BIOLOGICAL ABNORMALITIES IN THE MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE DISORDERS. CLINICS IN HAEMATOLOGY, 15(4), 973–93.
- REMISSION MAINTENANCE THERAPY IN ACUTE MYELOGENOUS LEUKEMIA
  EMBURY, S. H., ELIAS, L., HELLER, P. H., HOOD, C. E., GREENBERG, P. L., & SCHRIER, S. L. (1977). REMISSION MAINTENANCE THERAPY IN ACUTE MYELOGENOUS LEUKEMIA. CLINICAL RESEARCH, 25(2), A154.
- Classifying chronic myelomonocytic leukemia - In Reply
  Greenberg, P., Anderson, J., Estey, E., Fenaux, P., Hamblin, T., Hellstrom-Lindberg, E., … Zanz, M. (2001). Classifying chronic myelomonocytic leukemia - In Reply. JOURNAL OF CLINICAL ONCOLOGY, 19(17), 3791–92.
- HUMORAL AND CELLULAR ALTERATIONS IN CYCLIC NEUTROPENIA
  GREENBERG, P., BAX, LEVIN, J., & ANDREWS, T. (1975). HUMORAL AND CELLULAR ALTERATIONS IN CYCLIC NEUTROPENIA. CLINICAL RESEARCH, 23(3), A275.
- Quality of life in individuals with myelodysplastic syndromes (MDS): A descriptive study.
  Thomas, M. L., Zhang, J., & Greenberg, P. L. (1999). Quality of life in individuals with myelodysplastic syndromes (MDS): A descriptive study. BLOOD, 94(10), 662A.
- Phase II study of amifostine in patients with myelodysplastic syndromes (MDS).
  List, A. F., Holmes, H., Greenberg, P. L., Bennett, J. M., & Oster, W. (1999). Phase II study of amifostine in patients with myelodysplastic syndromes (MDS). BLOOD, 94(10), 305A.
- Phase II study of amifostine in patients with myelodysplastic syndromes (MDS): Impact on hematopoiesis.
  List, A. F., Holmes, H., Vempaty, H., Greenberg, P. L., & Bennett, J. M. (1998). Phase II study of amifostine in patients with myelodysplastic syndromes (MDS): Impact on hematopoiesis. BLOOD, 92(10), 714A.
- GRANULOPOIESIS IN MYELOPROLIFERATIVE DISORDERS
  GREENBERG, P., MARA, B., BAX, BROSSEL, R., & SCHRIER, S. (1975). GRANULOPOIESIS IN MYELOPROLIFERATIVE DISORDERS. BLOOD, 46(6), 1008.
- MONOCLONAL-ANTIBODY CHARACTERIZATION OF HUMAN MYELOID COLONY-FORMING CELLS (CFU-GM)
  GREENBERG, P., GROSSMAN, M., CHARRON, D., & LEVY, R. (1981). MONOCLONAL-ANTIBODY CHARACTERIZATION OF HUMAN MYELOID COLONY-FORMING CELLS (CFU-GM). CLINICAL RESEARCH, 29(1), A88.
- MULTIVARIATE-ANALYSIS OF FACTORS PREDICTING OUTCOME OF TREATMENT FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
  SCHWARTZ, R., HALPERN, J., & GREENBERG, P. (1980). MULTIVARIATE-ANALYSIS OF FACTORS PREDICTING OUTCOME OF TREATMENT FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML). PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 21(MAR), 435.
- Problematic WHO reclassification of myelodysplastic syndromes
  Greenberg, P., Anderson, J., de Witte, T., Estey, E., Fenaux, P., Gupta, P., … Willman, C. (2000). Problematic WHO reclassification of myelodysplastic syndromes. JOURNAL OF CLINICAL ONCOLOGY, 18(19), 3447–49.
- Soluble TNF receptor fusion protein (TNFR : Fc; Enbrel) in the treatment of patients with myelodysplastic syndrome (MDS).
  Deeg, H. J., Gotlib, J., Beckham, C., Dugan, K., Appelbaum, F., & Greenberg, P. (2000). Soluble TNF receptor fusion protein (TNFR : Fc; Enbrel) in the treatment of patients with myelodysplastic syndrome (MDS). BLOOD, 96(11), 146A.
- Amifostine in combination with cytokines stimulates in vitro hemopoiesis in myelodysplastic syndromes (MDS).
  Rajapaksa, R., Bhatia, S., Swarnakar, A., Kodali, U., & Greenberg, P. L. (1998). Amifostine in combination with cytokines stimulates in vitro hemopoiesis in myelodysplastic syndromes (MDS). BLOOD, 92(10), 160B.
- International prognostic scoring system and other prognostic systems for myelodysplastic syndromes - Response
  Greenberg, P., Cox, C., & Bennett, J. (1997). International prognostic scoring system and other prognostic systems for myelodysplastic syndromes - Response. BLOOD, 90(10), 4233–34.
- Efficacy of G-CSF and EPO on the anaemia in patients with myelodysplastic syndromes (MDS).
  HellstromLindberg, E., Negrin, R., Stein, R., Krantz, S., Vardiman, J., Ost, A., … Greenberg, P. (1995). Efficacy of G-CSF and EPO on the anaemia in patients with myelodysplastic syndromes (MDS). BLOOD, 86(10), 1340.
- International workshop consensus risk analysis system for myelodysplastic syndromes (MDS).
  Greenberg, P., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., … LeBeau, M. (1995). International workshop consensus risk analysis system for myelodysplastic syndromes (MDS). BLOOD, 86(10), 1065.
- GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) PLUS ERYTHROPOIETIN (EPO) FOR THE MAINTENANCE TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES (MDS)
  NEGRIN, R. S., STEIN, R., DOHERTY, K., CORNWELL, J., VARDIMAN, J., KRANTZ, S., & GREENBERG, P. L. (1994). GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) PLUS ERYTHROPOIETIN (EPO) FOR THE MAINTENANCE TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES (MDS). EXPERIMENTAL HEMATOLOGY, 22(8), 703.
- BCL-2 EXPRESSION BY MYELOID PRECURSORS IN MYELODYSPLASTIC SYNDROMES (MDS) - IMMUNOSTAINING OF BONE-MARROW (BM) BIOPSIES
  DAVIS, R. E., & GREENBERG, P. L. (1994). BCL-2 EXPRESSION BY MYELOID PRECURSORS IN MYELODYSPLASTIC SYNDROMES (MDS) - IMMUNOSTAINING OF BONE-MARROW (BM) BIOPSIES. BLOOD, 84(10), A314.
- ONCOPROTEIN EXPRESSION AND APOPTOSIS IN MYELODYSPLASTIC SYNDROME (MDS) MARROW-CELLS
  GREENBERG, P. L., GINZTON, N., & RAJAPAKSA, R. (1994). ONCOPROTEIN EXPRESSION AND APOPTOSIS IN MYELODYSPLASTIC SYNDROME (MDS) MARROW-CELLS. BLOOD, 84(10), A54.
- CLONALITY ANALYSIS IN MYELODYSPLASIA (MDS) PATIENTS TREATED WITH G-CSF
  KOHLER, S., BUSQUE, L., DEHART, D., LEBEAU, M., NEGRIN, R., GANSER, A., … GILLILAND, D. G. (1993). CLONALITY ANALYSIS IN MYELODYSPLASIA (MDS) PATIENTS TREATED WITH G-CSF. BLOOD, 82(10), A376.
- THE PROGNOSTIC-SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES (MDS) FOLLOWING G-CSF
  LEBEAU, M., TAYLOR, K., LARSON, R., KOEFFLER, P., NEGRIN, R., SABA, H., … GREENBERG, P. (1993). THE PROGNOSTIC-SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES (MDS) FOLLOWING G-CSF. BLOOD, 82(10), A375.
- GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) PLUS ERYTHROPOIETIN (EPO) TREATMENT OF MYELODYSPLASTIC SYNDROMES
  NEGRIN, R. S., DOHERTY, K., STEIN, R., VARDIMAN, J., KRANTZ, S., & GREENBERG, P. L. (1992). GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) PLUS ERYTHROPOIETIN (EPO) TREATMENT OF MYELODYSPLASTIC SYNDROMES. EXPERIMENTAL HEMATOLOGY, 20(6), 745.
- INVITRO-INVIVO CORRELATIONS OF ERYTHROID RESPONSES TO G-CSF PLUS ERYTHROPOIETIN (EPO) IN MYELODYSPLASTIC SYNDROMES (MDS)
  GREENBERG, P. L., NEGRIN, R. S., & GINZTON, N. (1992). INVITRO-INVIVO CORRELATIONS OF ERYTHROID RESPONSES TO G-CSF PLUS ERYTHROPOIETIN (EPO) IN MYELODYSPLASTIC SYNDROMES (MDS). EXPERIMENTAL HEMATOLOGY, 20(6), 733.
- CLINICAL USE OF MYELOID COLONY STIMULATING FACTORS (CSFS) IN MYELODYSPLASTIC SYNDROMES (MDS)
  GREENBERG, P. L. (1991). CLINICAL USE OF MYELOID COLONY STIMULATING FACTORS (CSFS) IN MYELODYSPLASTIC SYNDROMES (MDS). EXPERIMENTAL HEMATOLOGY, 19(6), 461.
- THE NATURE AND EVOLVING TREATMENT OF MYELODYSPLASTIC SYNDROMES
  GREENBERG, P. (1989). THE NATURE AND EVOLVING TREATMENT OF MYELODYSPLASTIC SYNDROMES. WESTERN JOURNAL OF MEDICINE, 151(2), 194–96.
- Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
  Platzbecker, U., Wong, R. S., Verma, A., Abboud, C., Araujo, S., Chiou, T.-J. J., … Giagounidis, A. (2015). Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. The Lancet. Haematology, 2(10), e417–26.
- Granulocyte-monocyte and Granulocyte-Colony Stimulating Factors in Myelodysplastic Syndromes.
  Nagler, A., & Greenberg, P. L. (1991). Granulocyte-monocyte and Granulocyte-Colony Stimulating Factors in Myelodysplastic Syndromes. Leukemia & Lymphoma, 5(4), 219–30.
- Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review
  Park, S., Greenberg, P., Yucel, A., Farmer, C., O'Neill, F., Brandao, C. D. O., & Fenaux, P. (2019). Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. BRITISH JOURNAL OF HAEMATOLOGY, 184(2), 134–60.
- Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy
  Aleshin, A., & Greenberg, P. L. (2018). Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy. BLOOD ADVANCES, 2(20), 2787–97.
- Recurrent drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling
  Aleshin, A., Medeiros, B. C., Kamble, S., Heiser, D., Santaguida, M., Prashad, S., & Greenberg, P. L. (2018). Recurrent drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling. CANCER RESEARCH, 78(13).
- Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression
  Aleshin, A., Greenberg, P. L., Medeiros, B. C., Heiser, D., Santaguida, M., Prashad, S., … Eastburn, D. J. (2018). Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression. CANCER RESEARCH, 78(13).
- TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
  Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., … Bejar, R. (2019). TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. LEUKEMIA, 33(7), 1747–58.
- MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-beta pathways.
  Youn, M., Huang, H., Chen, C., Kam, S., Wilkes, M. C., Chae, H.-D., … Sakamoto, K. M. (2019). MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-beta pathways. Blood Advances, 3(18), 2751–63.
- Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
  Valent, P., Orazi, A., Savona, M. R., Patnaik, M. M., Onida, F., van de Loosdrecht, A. A., … Bennett, J. M. (2019). Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. HAEMATOLOGICA, 104(10), 1935–49.
- PROPOSAL OF A NEW, COMPREHENSIVE CYTOGENETIC SCORING SYSTEM FOR PRIMARY MDS
  Schanz, J., Tuechler, H., Sole, F., Mallo, M., Hildebrandt, B., Slovak, M., … Haase, D. (2010). PROPOSAL OF A NEW, COMPREHENSIVE CYTOGENETIC SCORING SYSTEM FOR PRIMARY MDS. HAEMATOLOGICA, 95, 219.
- CHRONICALLY TRANSFUSED MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS HAVE SEVERE IRON BURDEN: DEFERASIROX TREATMENT REDUCES IRON OVERLOAD AND IMPROVES LIVER FUNCTION
  Gattermann, N., Greenberg, P., Urabe, A., Habr, D., Kpamegan, E., & Porter, J. (2012). CHRONICALLY TRANSFUSED MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS HAVE SEVERE IRON BURDEN: DEFERASIROX TREATMENT REDUCES IRON OVERLOAD AND IMPROVES LIVER FUNCTION. HAEMATOLOGICA, 97, 138.
- Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.
  Atallah, E., Logan, B., Chen, M., Cutler, C., Deeg, J., Jacoby, M., … Rizzo, J. D. (2019). Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncology.
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
  Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., … List, A. F. (2020). Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. The New England Journal of Medicine, 382(2), 140–51.
- Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.
  Behbehani, G. K., Finck, R., Samusik, N., Sridhar, K., Fantl, W. J., Greenberg, P. L., & Nolan, G. P. (2020). Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation. Cytometry. Part B, Clinical Cytometry.
- Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.
  Pine, A. B., Chokr, N., Stahl, M., Steensma, D. P., Sekeres, M. A., Litzow, M. R., … Zeidan, A. M. (2020). Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma, 1–10.
- Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
  Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montano Figueroa, E. H., … Garcia-Manero, G. (2020). Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Annals of Internal Medicine.
- SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM).
  Malcovati, L., Stevenson, K., Papaemmanuil, E., Neuberg, D., Bejar, R., Boultwood, J., … Cazzola, M. (2020). SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood.
- Myelodysplastic syndromes: moving towards personalized management.
  Hellström-Lindberg, E., Tobiasson, M., & Greenberg, P. (2020). Myelodysplastic syndromes: moving towards personalized management. Haematologica.
- Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
  Azizi, A., Ediriwickrema, A., Dutta, R., Patel, S. A., Shomali, W., Medeiros, B., … Zhang, T. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia & Lymphoma, 1–8.
- Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms.
  Spinner, M. A., Aleshin, A., Santaguida, M. T., Schaffert, S. A., Zehnder, J. L., Patterson, A. S., … Greenberg, P. L. (2020). Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Blood Advances, 4(12), 2768–78.
- Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
  Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., … Sanz, G. (2020). Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia.
- Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations.
  Feurstein, S., Adegunsoye, A., Mojsilovic, D., Vij, R., West DePersia, A. H., Rajagopal, P. S., … Churpek, J. E. (2020). Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Advances, 4(19), 4873–86.
- Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
  Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., … Papaemmanuil, E. (2021). Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020). NATURE MEDICINE.
- A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis
  Komrokji, R. S., Platzbecker, U., Fenaux, P., Garcia-Manero, G., Mufti, G. J., Santini, V., … Verma, A. (2021). A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis. BRITISH JOURNAL OF HAEMATOLOGY, 193, 67–68.
- Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
  Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., … Platzbecker, U. (2021). Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia.
- Metchnikoff's inflamed legacy: the dysplastic nature of myelodysplastic syndrome's innate Immunity.
  Greenberg, P. L. (2021). Metchnikoff's inflamed legacy: the dysplastic nature of myelodysplastic syndrome's innate Immunity. Haematologica.
- COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
  Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., … Sanz, G. (2021). COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS). LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
- Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.
  Gerds, A. T., Scott, B. L., Greenberg, P. L., Lin, T. L., Pollyea, D. A., Verma, A. K., … Donnellan, W. B. (1800). Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances.
- NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022.
  Greenberg, P. L., Stone, R. M., Al-Kali, A., Bennett, J. M., Borate, U., Brunner, A. M., … Hochstetler, C. (2022). NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network : JNCCN, 20(2), 106–117.
- Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
  Komrokji, R. S., Platzbecker, U., Fenaux, P., Zeidan, A. M., Garcia-Manero, G., Mufti, G. J., … Verma, A. (2022). Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia.
- Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
  Zeidan, A. M., Platzbecker, U., Garcia-Manero, G., Sekeres, M. A., Fenaux, P., DeZern, A. E., … Komrokji, R. S. (2022). Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood.
- MDS and MDS/MPN Genomic Subgroups Demonstrate Differential E x Vivo Drug Sensitivity
  Spinner, M. A., Schaffert, S. A., Stehr, H., TSantaguida, M., Kita, R., Aleshin, A., … Greenberg, P. L. (2021). MDS and MDS/MPN Genomic Subgroups Demonstrate Differential E x Vivo Drug Sensitivity. BLOOD. AMER SOC HEMATOLOGY.
- An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).
  Stahl, M., Abdel-Wahab, O., Wei, A. H., Savona, M. R., Xu, M. L., Xie, Z., … Zeidan, A. M. (2022). An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood Advances.
- Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
  Zeidan, A. M., Bewersdorf, J. P., Buckstein, R., Sekeres, M. A., Steensma, D. P., Platzbecker, U., … Santini, V. (2022). Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia.
- Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
  DeZern, A. E., & Greenberg, P. L. (2022). Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms. Journal of the National Comprehensive Cancer Network : JNCCN, 20(12), 1280–1283.
- Myelodysplastic syndromes, thy name is heterogeneity.
  Greenberg, P. L. (2023). Myelodysplastic syndromes, thy name is heterogeneity. British Journal of Haematology.
- Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
  Pfeilstocker, M., Tuechler, H., Ades, L., Cermak, J., Chermat, F., Della Porta, M. G., … Greenberg, P. L. (2022). Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories. BLOOD. AMER SOC HEMATOLOGY.
- Correlation of Mutational Profiles and Cytogenetics with Morphologic Dysplasia in Myelodysplastic Syndromes
  Kumar, J., Khanna, V., Lu, R., Stehr, H., Spinner, M. A., Silva, O., … Tan, B. (2022). Correlation of Mutational Profiles and Cytogenetics with Morphologic Dysplasia in Myelodysplastic Syndromes. BLOOD. AMER SOC HEMATOLOGY.
- Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
  Sirenko, M., Bernard, E., Beck, D. B., Creignou, M., Domenico, D., Farina, A., … Papaemmanuil, E. (2022). Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS. BLOOD. AMER SOC HEMATOLOGY.
- A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
  Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., … Sanz, G. (2023). A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS). LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
- ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE
  Pfeilstoecker, M., Tuechler, H., Ades, L., Cermak, J., Chermat, F., Della Porta, M., … Greenberg, P. (2023). ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE. LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
- GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
  Bernard, E., Hasserjian, R., Greenberg, P., Ossa, J. A., Creignou, M., Nannya, Y., … Papaemmanuil, E. (2023). GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES. LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
- Prognostication and risk stratification of patients with myelodysplastic syndromes.
  DeZern, A., & Greenberg, P. L. (2023). Prognostication and risk stratification of patients with myelodysplastic syndromes. Blood.
- Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
  Stahl, M., Bewersdorf, J. P., Xie, Z., Porta, M. G., Komrokji, R., Xu, M. L., … Zeidan, A. M. (2023). Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews, 101128.
- SIRT7 IMPROVES HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROME THROUGH REGULATING MITOCHONDRIAL STRESS
  Wang, Y., Maruichi, A., song, Z., Greenberg, P., & Chen, D. (2023). SIRT7 IMPROVES HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROME THROUGH REGULATING MITOCHONDRIAL STRESS. EXPERIMENTAL HEMATOLOGY. ELSEVIER SCIENCE INC.
- The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
  Khanna, V., Lu, R., Kumar, J., Molina, A., Stehr, H., Spiteri, E., … Greenberg, P. L. (2023). The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms. Leukemia Research, 136, 107433.
- How we reduce and treat post-transplant relapse of MDS.
  Mina, A., Greenberg, P. L., & Deeg, H. J. (2024). How we reduce and treat post-transplant relapse of MDS. Blood.
- Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
  Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., … Papaemmanuil, E. (2022). Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence, 1(7), EVIDoa2200008.
- Shared and distinct mechanisms of UBA1 inactivation across different diseases.
  Collins, J. C., Magaziner, S. J., English, M., Hassan, B., Chen, X., Balanda, N., … Werner, A. (2024). Shared and distinct mechanisms of UBA1 inactivation across different diseases. The EMBO Journal.
- Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
  Bernard, E., Hasserjian, R., Greenberg, P. L., Ossa, J. E. A., Creignou, M., Nannya, Y., … Papaemmanuil, E. (2023). Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications. BLOOD. AMER SOC HEMATOLOGY.
- Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
  Garcia-Manero, G., Ooi, M., Lao, Z., Gill, H., Abaza, Y., Stahl, M., … Woo, J. (2023). Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study. BLOOD. AMER SOC HEMATOLOGY.
- p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
  Brar, N., Lawrence, L., Fung, E., Zehnder, J. L., Greenberg, P. L., Mannis, G. N., … Fernandez-Pol, S. (2024). p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes. American Journal of Clinical Pathology.
- Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
  Sirenko, M., Bernard, E., Creignou, M., Domenico, D., Farina, A., Arango Ossa, J. E., … Pinheiro, R. F. (2024). Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood.
- Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
  Efficace, F., Buckstein, R., Abel, G. A., Giesinger, J. M., Fenaux, P., Bewersdorf, J. P., … Zeidan, A. M. (2024). Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS). HemaSphere, 8(5), e69.
- Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.
  Bernard, E., Hasserjian, R. P., Greenberg, P. L., Arango Ossa, J. E., Creignou, M., Tuechler, H., … Papaemmanuil, E. (2024). Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications. Blood.
- Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).
  Aakash, F., Gisriel, S. D., Zeidan, A. M., Bennett, J. M., Bejar, R., Bewersdorf, J. P., … Loghavi, S. (2024). Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS). Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 100615.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

Biologically Focused Therapy of Treatment-Refractory MDS Patients

A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Specializing In

Chronic Myelomonocytic Leukemia
Leukemia
Multiple Myeloma

Practice Locations

Hematologic Cancer Program Palo Alto, CA

Palo Alto, CA

Hematologic Cancer Program

875 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(4 Ratings)

Overall Rating

5.0/5

View Ratings by Category

5.0/5

Friendliness

5.0/5

Explanations

5.0/5

Listens

5.0/5

Care provider's efforts to include you in decisions about your care

5.0/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(97 reviews)

Excellent doctor Knolagable and addressed all of my questions

Nov 2024

•

Verified SHC Patient

Dr. Greenberg is an excellent communicator. He patiently discuss my diagnosis and treatment throughly and answer all my questions. I felt better after talking to him.

Oct 2024

•

Verified SHC Patient

He is experienced, understanding and informative. Can't say enough good things about Dr. Greenberg.

Oct 2024

•

Verified SHC Patient

I appreciate very much how clearly he described by condition and how he and his office will be monitoring that condition in the future. He explained everything in a very calm, positive way. Thank you Dr. Greenberg!

Sep 2024

•

Verified SHC Patient

Dr. Greenberg seems like a nice man and good doctor. All my visits have been phone calls so I have never had face to face interaction.

Aug 2024

•

Verified SHC Patient

very professional, easy to understand

Jul 2024

•

Verified SHC Patient

Great doctor

Jun 2024

•

Verified SHC Patient

He is a excellent doctor and I depend on him for his expertise.

May 2024

•

Verified SHC Patient

It was very convenient to be able to talk with Dr. Greenberg on the phone instead of virtually.

May 2024

•

Verified SHC Patient

I enjoyed talking with Dr. Greenberg and Dr. Wallace. They are both very knowledgeable and nice.

May 2024

•

Verified SHC Patient

He was very helpful and answered all my questions. Very knowledgeable about my disease.

May 2024

•

Verified SHC Patient

I would prefer an actual video visit rather than a phone call.

May 2024

•

Verified SHC Patient

Provided a great deal of information and made a point of answering all my questions. Visit Summary was posted the same day which I appreciate.

Apr 2024

•

Verified SHC Patient

Dr Greenberg was very detailed and very clear passing the required information to me. Dr Greenberg answered all my questions and concerns very clearly and in details to my satisfaction. I highly recommend Dr Greenberg to any patient for consultation and treatment.

Apr 2024

•

Verified SHC Patient

He is very patient & explains everything clearly. Always answers all my questions.

Mar 2024

•

Verified SHC Patient

Dr Greenberg was very helpful, empathetic and knowledgeable and encouraging. He took a personal interest in me as a person and I appreciate his professionalism. He has excellent bedside manner.

Feb 2024

•

Verified SHC Patient

Dr Greenberg was wonderful and explained what he thought might help my condition. I feel very fortunate to have his opinion.

Feb 2024

•

Verified SHC Patient

Lovely man

Feb 2024

•

Verified SHC Patient

A nice, very knowledgeable doctor. I grad to visit him today. I would like he will support me in the future.

Feb 2024

•

Verified SHC Patient

Excellent, empathetic, expert.

Jan 2024

•

Verified SHC Patient

Clear and direct interactions.

Dec 2023

•

Verified SHC Patient

Dr Peter Greenberg is a good listener,, has kindly explained to me about my very-high-risk MDS and had an efficient plan with a BMT Team for my BMT procedure that may occurred in few weeks. With my deep appreciations to Dr Peter Greenberg and the BMT Team of the Stanford Hospital!

Dec 2023

•

Verified SHC Patient

I have only visited with him x2, however, I find him to be professional, to the point, trustworthy, and he has a very nice demeanor. He makes me feel comfortable which is very important.

Nov 2023

•

Verified SHC Patient

He is knowledgeable and patient. He does not rush through the visit and is very responsive to my questions. I greatly appreciate him!

Oct 2023

•

Verified SHC Patient

Very professional, informative

Oct 2023

•

Verified SHC Patient

He was very friendly and professional.

Sep 2023

•

Verified SHC Patient

Dr. Greenberg is an excellent Doctor and our conversations are very productive, but I wish we didn't try to coordinate a video conference, because we have never had one.

Aug 2023

•

Verified SHC Patient

He is an absolutely outstanding physician. He never gave up on me, as other doctors have. He pursues solutions. I feel very fortunate,

Aug 2023

•

Verified SHC Patient

great doctor with a warm heart.

Jul 2023

•

Verified SHC Patient

Very thoughtful and thorough

Jul 2023

•

Verified SHC Patient

He was extremely knowledgeable and very informative

Jul 2023

•

Verified SHC Patient

Dr. Greenberg is obviously a world-class expert in his field. He was clear, concise, thorough, and helpful.

Jul 2023

•

Verified SHC Patient

Responsive, cordial and prepared.

Jul 2023

•

Verified SHC Patient

I met him for the first time. He appears thorough and informative. He is very polite and gentle. Not alarming in any way. I hope to meet him on person some day.

Jun 2023

•

Verified SHC Patient

He is an outstanding doctor. I feel fortunate to be in his care.

May 2023

•

Verified SHC Patient

Greenberg was cordial and informed. Good man.

May 2023

•

Verified SHC Patient

Efficient and professional.

May 2023

•

Verified SHC Patient

He was on time, answered all my questions, scheduled a follow-up appointment.

May 2023

•

Verified SHC Patient

Very Knowledgeable and Good Dr.

May 2023

•

Verified SHC Patient

thoughtful and clear. I appreciate his time for this consult

May 2023

•

Verified SHC Patient

Excellent bedside manner

Apr 2023

•

Verified SHC Patient

GREAT!

Mar 2023

•

Verified SHC Patient

Dr. Greenberg is wonderful and I feel extremely lucky to have him as my Doctor

Mar 2023

•

Verified SHC Patient

thank you so much

Feb 2023

•

Verified SHC Patient

Extremely professional, listened to my concerns, and provided me with excellent advice. I'm lucky to have gotten an appointment with him.

Nov 2022

•

Verified SHC Patient

I liked him and his associate very much, they made me feel at ease in explaining my condition and I feel confident with the answers he gave me and what to be aware of in my future labs. It was a great choice to be a part of Standford Health Care.

Nov 2022

•

Verified SHC Patient

Dr Greenberg is an outstanding oncologist who answered all of my questions.

Oct 2022

•

Verified SHC Patient

He is excellent, patient and kind and answered all my questions.

Oct 2022

•

Verified SHC Patient

Wonderful, caring and knowledgeable person. 10 stars.

Oct 2022

•

Verified SHC Patient

Thank you for your help Dr Greenberg...thank you.

Sep 2022

•

Verified SHC Patient

Dr. Greenberg shows great concern about my condition and is very clear about my care an what is needed to try and curtail my cancer. He leaves no question unanswered and is quite thorough and professional in conduction our conversations.

Jul 2022

•

Verified SHC Patient

Dr. Greenberg is extremely knowledgeable and really takes the time to listen and explain everything in terms I can understand. He answered all my questions and put forth a plan for me which I truly appreciate.

Jul 2022

•

Verified SHC Patient

dr greenberg appeared to be very knowledgeable and very thorough about discussing all aspects of my proposed treatment and care.

May 2022

•

Verified SHC Patient

He is a wonderful doctor.

Apr 2022

•

Verified SHC Patient

Dr. Greenberg explained things in a very understandable way and asked me multiple time if I had any questions. I feel lucky to have been able to talk with him. He was very pleasant to talk with. The video visit went well despite technical issues on my end. Dr. Greenberg was able to work around my technical issues.

Mar 2022

•

Verified SHC Patient

Was a nice experience.

Mar 2022

•

Verified SHC Patient

Dr P. Greenberg is professional and gave me adequate answers to all my questions. He is fully aware of my medical situation and is interested to help me now and in the future.

Feb 2022

•

Verified SHC Patient

sounded like a good person

Feb 2022

•

Verified SHC Patient

Completely satisfied.

Feb 2022

•

Verified SHC Patient

Kind, reassuring and very much appreciated Dr. Greenbergs' advice. Including, his commitment to be available to consult with my healthcare providers.

Nov 2021

•

Verified SHC Patient

I was comfortable talking with him. He was familiar with my records, provided new information, and answered my questions.

Oct 2021

•

Verified SHC Patient

Dr Peter Greenberg was prepared to answer my questions. He is knowledgeable and knows the details of my case. He is caring and interested to do more test to help me. God bless him. Thank you.

Oct 2021

•

Verified SHC Patient

Dr. Greenberg provided detailed and insightful information on my condition, diagnosis, and treatment options.

Sep 2021

•

Verified SHC Patient

Calm, collected and professional.

Sep 2021

•

Verified SHC Patient

Thank you for speaking with me as quickly as you did.

Sep 2021

•

Verified SHC Patient

He is extremely great and well explained and understood. I am very pleased with him and Dr schwed

Sep 2021

•

Verified SHC Patient

again, the sound quality. very nice and caring man.

Aug 2021

•

Verified SHC Patient

He was calm and patient. He asked how I felt. He discussed my condition with me. He explained his recommendations that he would communicate to my doctor

Jul 2021

•

Verified SHC Patient

Dr. Greenberg is superb!! I wish he could be cloned. More doctors like him, especially in oncology, would make my life easier.

Feb 2020

•

Verified SHC Patient

The absolute best in the west.

Aug 2019

•

Verified SHC Patient

I really like Dr. Greenberg, and the visit was very helpful. I wish I could return again.

Apr 2019

•

Verified SHC Patient

Very professional.

Mar 2019

•

Verified SHC Patient

Very good experience.

Jul 2018

•

Verified SHC Patient

All of them are very good.

Mar 2018

•

Verified SHC Patient

Extremely professional.

Mar 2018

•

Verified SHC Patient

Dr. Brar is the best.

Feb 2018

•

Verified SHC Patient

Drs. Aleshin and Greenberg were very empathetic and helpful.

Dec 2017

•

Verified SHC Patient

I just love coming to Stanford. Everyone is working at the top of their field!!

Sep 2017

•

Verified SHC Patient

Dr. Greenberg is the BEST!!

Aug 2017

•

Verified SHC Patient

Dr. Greenberg is an EXCELLENT physician! He is extremely knowledgeable, kind and caring.

Jul 2017

•

Verified SHC Patient

Excellent. Love Dr. Greenberg!

Apr 2017

•

Verified SHC Patient

Dr. Greenberg's fellow, Alex, did a great job explaining my medical condition and treatment options.

Dec 2016

•

Verified SHC Patient

Great second opinion (Dr. Greenberg) in line w/Dr. Jonas, who was student of Dr. Greenberg.

Dec 2016

•

Verified SHC Patient

Good Dr. Peter Greenberg need I say more? Excellent.

Sep 2016

•

Verified SHC Patient

Never felt rushed - were very informative and I was able to understand. They suggested I record the conversations with the doctor in my phone. Great idea!

Apr 2016

•

Verified SHC Patient

They were great. Never felt rushed and explained things very well!

Apr 2016

•

Verified SHC Patient

Dr. P. Greenberg is an outstanding provider, person.

Nov 2015

•

Verified SHC Patient

Very impressed with Dr. Greenberg.

May 2015

•

Verified SHC Patient

I would recommend this doctor without reservation.

Apr 2015

•

Verified SHC Patient

Appreciated Dr. Greenberg's expertise of MDs.

Apr 2015

•

Verified SHC Patient

Good.

Apr 2015

•

Verified SHC Patient

Words I did not understand were re-phrased.

Mar 2015

•

Verified SHC Patient

I've always (38 yrs as an MD) told or sent all my pts. & friends with serious medical problems to be seen at Stanford.

Feb 2015

•

Verified SHC Patient

I came there for a diagnosis treatment, and prognosis and left with none of those -

Feb 2015

•

Verified SHC Patient

Extremely compassionate and caring putting patient at ease.

May 2014

•

Verified SHC Patient

He was considerate encouraging & seemed interested in me & he told me I could call him!

May 2014

•

Verified SHC Patient

Dr. Greenberg provided an excellent support. Thanks to him.

Apr 2014

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Peter Greenberg

Hematologist-Oncologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Hematologic Cancer Program Palo Alto, CA

Hematologic Cancer Program

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(97 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Peter Greenberg

Hematologist-Oncologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Hematologic Cancer Program Palo Alto, CA

Hematologic Cancer Program

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(97 reviews)

Referring Physicians

PHYSICIAN HELPLINE